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Abbreviations 
  Antibody binding cassettes ABCs 
Auxin response factors ARF 
American type cell culture ATCC 
Adenosine triphosphate ATP 
Bone marrow derived dendritic cells BMDCs 
8-chloromethyl-4,4-difluoro-1,3,5,7-tetramethyl-4-bora- 3a,4a-diaza-s-indacene BODIPY 
Bovine serum albumin BSA 
4-chloromethyl-benzoyl-amino-tetra methyl-rhodamine CMTMR 
4(or 5)(4-(chloromethyl)benzamido)-2-(1,2,2,4,8,10,10,11-octamethyl-1,2,10,11-
tetrahydropyrano[3,2-g:5,6-g']diquinolin-13-ium-6-yl)benzoate CMTPX 
Circulating tumour cells CTCs 
4',6-diamidino-2-phenylindole DAPI 
diaphanous-related formin 3 DIAPH3 
Dulbecco’s modified eagle's medium DMEM 
Deoxyribonucleic acid DNA 
Deoxynucleotide triphosphate dNTP 
Deoxyuridine triphosphate dUTP 
Deep vein thrombosis DVT 
Ethylene-diamine-tetra-acetic acid EDTA 
Epithelial growth factor receptor EGFR 
Epithelial mesenchymal transition EMT 
Extracellular vesicles EV 
Fetal bovine serum FBS 
Glutaraldehyde GAD 
Guanosine diphosphate GDP 
Green fluorescent protein GFP 
Guanosine triphosphate GTP 
Immunoglobulin-G IgG 
Infrared IR 
Large oncosomes LO 
Lox-Stop-Lox LSL 
Metastasis associated macrophages MAMs 
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Myeloid derived stem cells MDSCs 
Minimal essential medium MEM 
Microvesicles MVs 
Natural killer NK 
Pancreatic intraepithelial neoplasia PanIN 
Phosphate buffer saline PBS 
Polymerase chain reaction PCR 
Pancreatic ductal adenocarcinoma PDAC 
Phosphatidylethanolamine PE 
Paraformaldehyde PFA 
Phosphatidylserine PS 
Ribonucleic acid RNA 
Roswell Park Memorial Institute RPMI 
Room Temperature RT 
Reverse transcriptase- polymerase chain reaction RT-PCR 
Scanning electron microscopy SEM 
Tumour associated macrophages TAMs 
Thromboelastography TEG 
Tissue factor TF 
Tumour growth factor TGF 
Tumour microvesicles TMVs 
Tissue necrosis factor TNF 
Terminal deoxynucleotidyl transferase dUTP nick end labelling TUNEL 
Vesicle associated membrane protein VAMP 
Vascular endothelial growth factor VEGF 
Vascular endothelial growth factor receptor VGFR 
White blood cells WBCs 
Wild type WT 
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1.  Introduction 
1.1. Pancreatic Carcinoma               
        Pancreatic cancer is currently the 5th leading cause of death due to cancer with a 5 year 
survival rate of <5%1. The underlying causes of this disease are still obscure. Due to its poor 
prognosis pancreatic cancer is expected to become the 2nd largest cause of deaths due to cancer 
in the future2,3. Given the lack of disease specific markers and of sensitive screening methods, 
detection of pancreatic cancer in early stages is difficult4. Usually the disease is detected 
clinically only when distant metastasis has already occurred. Pancreatic cancer metastasises most 
commonly in the liver (76-94%), peritoneum (41-56%) and the lung5,6,7,8. The current treatment 
regimens for pancreatic cancer include surgical techniques such as curative surgeries (distal 
pancreatectomy, total pancreatectomy and pancreaticoduodenectomy also known as Whipple 
method) and palliative surgery (blocking of the common bile duct) as well as chemotherapeutics 
including gemcitabine, FOLFIRINOX, a combination of gemcitabine and nab-paclitaxel and 
radiation therapies9,10. There are essentially two major types of pancreatic cancer, the endocrine 
type which accounts for less than 5% of tumours detected in pancreatic cancer patients and the 
exocrine type constituting 95% of the tumours are11. Exocrine pancreatic cancer can be further 
classified as adenocarcinomas (accounting for 90% of pancreatic cancers), acinar cell carcinoma 
(rarely occurring), Intraductal Papillary-Mucinous Neoplasm (IPMN; cystic tumour) and 
Mucinous Cystadenocarcinoma (rarely occurring malignant cystic tumour)12,13. 
 
1.1.1. Pancreatic ductal adenocarcinoma (PDAC)  
                  PDAC is the most frequently occurring form of pancreatic cancer, which is known to 
be a highly aggressive form of exocrine cancer and is usually accompanied by distant 
metastasis14. These carcinomas are often diagnosed in the advanced stages and show resistance 
to treatments due to which the median survival period is approximately 4 months at the time of 
diagnosis12,15. PDAC usually progresses with increasing stages of dysplasia and nuclear atypia 
presented as a series of pancreatic intraepithelial neoplasia (PanINs)16. The different stages of 
PDAC are indicated in Fig. 1a, and are as follows 1) PanIN-1A characterised with flat epithelial 
lesions made up of tall columnar cells with basal nucleus; 2) PanIN-1B are similar to typa1A 
except  
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Figure 1: A schematic representation of the progression of PDAC. Genetic mutations triggered with respect to the 
stages of progression. Adapted from17. 
 
that they show some papillary or micropapillary architecture of the ducts; 3) PanIN-2 show 
mucinous epithelial lesions with cells showing nuclear abnormalities; 4) PanIN-3 have papillary 
lesions with small clusters of epithelial cells budding off in lumen (cribriforming) along with 
luminal necrosis, nuclear irregularities and faulty mitosis (Fig. 1a)6,18. Moreover, the disease shows 
reproducible genetic mutations which are characteristic of each stage of progression of the disease 
(Fig. 1)19. Genetically engineered mouse models have helped to establish that mutations which lead 
to constitutively active KRAS are the earliest to occur in most cases of PDACs i.e. the first two 
stages. Further progression of the disease is accompanied by sequential inactivation of various 
tumour suppressor genes (TSGs) (Fig. 1)16. In case of tumorigenesis, the TSGs CDKN2A, TP53 
and SMAD4/DPC4 are functionally inactivated20. CDKN2A encodes the p16/INK4A protein 
(cyclin-dependent kinase inhibitor) which is the earliest and most frequently suppressed gene (95% 
cases of PDACs tumours)18. In cells, activation of the KRAS oncogene triggers a p16-induced 
senescence. As a result of which, during early stages of PDACs, CDKN2A suppression is observed 
as an immediate consequence of KRAS activation further inhibiting the senescence response21,17. 
Another important gene, the TP53 gene which encodes for the tumor-suppressor protein p53 is 
frequently found to display missense mutation leading to inactivation of p53. It is generally 
observed in advanced PanINs following the inactivation of CDKN2A. As a result of the 
dysfunctional mutant p53, the expression of downstream genes that promote apoptosis 
(CDKN1A/p21, BAX, NOXA and PUMA) is hindered. Similar to TP53, the suppression of SMAD4 
also occurs during advanced stages of PDAC. Some other sporadic mutations in LKB1, SHH and 
BRACA1/2 genes also have been reported13. 
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1.2. Immune education 
        The progression of PDAC is accompanied by the formation of desmoplasia, a significant 
event convoyed by infiltration of various immune cell populations that are a part of the host 
immune response22. Such immune responses consist of a mixed population of cells that can be 
both tumour-suppressive as well as tumour-promoting23. The concept of immune editing 
proposes that since the immune system is naturally programmed to recognise and eliminate 
cancer as a result of which the tumour cells are stressed24. Therefore, in order to proliferate and 
survive, the cancer cells attempt to resist, avoid, or suppress this antitumor immune response, 
leading to immune-escape and tumour-promotion25. The process of immune editing consists of 
three phases (i) elimination, (ii) equilibrium and (iii) escape (Fig. 2). 
                
Figure 2: Three stages of immune editing. I) Elimination: cytotoxic immune cells such as CD8+T, CD4+ T cells as 
well as NK cells along with other immune cells elicit a strong response resulting in tumour cell apoptosis and 
elimination of the cancer. Ii) Equilibrium: the tumour cells begin to surpass the immune response, but the growth of 
the cancer remains limited. Escape: Tumour cells escape the immune surveillance and start to disseminate from 
primary sites progressing towards the development of metastasis. Adapted from26. 
 
During the first phase, the transformed cells and neoplasia are almost completely and selectively 
destroyed. This destruction is mainly mediated by cytotoxic T-cells and natural killer cells that 
are majorly responsible for eliminating cancer cells. In addition, CD8+T cells and NK cells also 
have the potential to restrict the metastatic growth of cancer cells27. The second phase of 
equilibrium occurs in the case of inefficient elimination of the neoplasia which is mainly due to 
acquired mutations by the tumour cells that render them resistant to the killing. The tumour cells 
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and the immune system therefore are in a dynamic equilibrium which keeps the tumour 
expansion under check further limiting its growth. As a consequence of this selective pressure on 
the tumour growth some clones might emerge which are completely resistant to the host immune 
response. These cells exhibit various mechanisms to surpass immune recognition, including 
various tumour derived factors in its microenvironment, which is seen in most cases of 
PDACs28,29. Therefore, the third phase is where the immune cells are said to escape and survive 
in distant areas. However, the tumour not only evades the immune surveillance but also engages 
the immune cells for the development of pre-metastatic niche followed by distant fully blown 
metastasis. To achieve this the tumour cells engage several processes such as promotion of 
immunosuppressive cells, induction of T cell apoptosis or hinder immune cell maturation30. 
 
1.3. Pre-metastatic niche formation 
        The concept of pre-metastatic niche was established in 1889 by Stephan Paget, which 
concluded that metastasis was not a random event but rather a very selective process where 
specific tumour cells, “the seed”, grow preferentially in a specific microenvironment of certain 
organs, “the soil”. Primary tumour cells can support the initiation of pre-metastatic niche 
formation at distant sites by secreting various growth factors, cytokines and extracellular 
vesicles. Overall, these factors promote the infiltration of cells towards future metastatic sites31. 
Tumour-derived secreted factors such as vascular endothelial growth factor (VEGF), tissue 
necrosis factor α (TNF-α), tumour growth factor β (TGF-β), Lysyl oxidase (LOX) are involved 
in the formation of a pre-metastatic niche in different tumour types32,33,34. The priming of the 
organ by such factors is thus involved in favouring the tumour cell colonisation of target organ35. 
Due to its unique biology, liver is a major target organ for most cancers namely pancreatic 
carcinomas, stomach, breast, colon, oesophagus, myelomas and leukaemia36. The infiltration of 
myeloid derived suppressor cells (MDSCs), neutrophils, macrophages and other bone marrow 
derived cells (BMDCs) into the liver tissue is crucial for the establishment of a pre-metastatic 
niche. Before the arrival of the metastatic tumour cells, BMDCs expressing vascular endothelial 
growth factor receptor 1 (VGFR-1) arrive at a distant receptive microenvironment32. Hiratsuka et 
al. provided the first evidence that non-neoplastic cells prime pre-metastatic niche sites33. He 
shows that BMDCs express CD133 and CD4, which are the markers for progenitor cells, along 
with integrin α4β1, a ligand for fibronectin that is known to be upregulated at distant metastatic 
sites. Secretion of VEGF-A, TNF-α and TGF-β by primary tumour cells also trigger a pro-
inflammatory response, which attracts myeloid cells to the site of premetastasis, thus paving the 
way for metastasis37. 
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1.4. Metastasis 
        Metastasis accounts for the most number of deaths associated with PDAC, even in cases of 
successful extraction of primary tumour with no clinical detection of spreading of the tumour 
during the time of surgery27. The process of metastasis occurs via sequential events leading to 
the spread cancer cells from the site of primary tumour to distal sites. First, at the site of the 
primary tumour, the tumour cells invade neighbouring tissue by escaping the tumouricidal 
immune response. These tumour cells secrete systemic factors in order to prime distant 
metastatic sites. The primary tumour microenvironment is altered to aid the egress of the cancer 
cells into the blood stream, such as by increasing the angiogenesis38. The tumour cells 
intravasate into the blood stream directly or via the lymphatic system. The survival of circulating 
cancer cells, after intravasation, has been suggested to be supported by the formation of a fibrin 
clot by platelets and tumour associated macrophages (TAMs)39. The cancer cells circulate with 
the bloodstream and are arrested in a microvascular bed, at a future metastatic site. This tumour 
cell arrest is termed as micro-circulatory arrest. The arrested cells then extravasate at these 
metastatic sites escaping the immune surveillance in the blood stream. Extravasation is assisted 
by metastasis associated macrophages (MAMs), which aid in the increase of vascular 
permeability. The extravasated cells then proliferate at these sites to initiate the formation of 
metastatic foci. Eventually the diverse aspects like blood supply, extracellular matrix and 
immune response are altered so as to promote the progression of metastasis at the metastatic 
site40,25. Especially in PDAC the migratory properties gained by the primary tumour cells is a 
result of a complex and less understood process called epithelial to mesenchymal transformation 
(EMT) or vice versa MET41. Although the actual involvement of EMT/ MET in PDAC 
metastasis is still under question this process of rapid transition has been known to be involved 
to increase the cancer cell motility and dissemination42. 
 
1.5. Extracellular vesicles (EVs) 
        The term extracellular vesicles (EVs) can be defined as any membrane bound particle 
carrying complex cargoes, including proteins, lipids and nucleic acids which can be released by 
any type of cell. They can be classified based on their cellular origin and biogenesis which also 
defines the type of cargo it might carry. Among the different types of EVs there are the 
exosomes (50-100 nm) formed via endo-lysosomal pathway, microvesicles (MVs) formed by 
outward blebbing of the plasma membrane (0.1-1 µm) and oncosomes (1-10 µm) mainly 
released by rapidly proliferating cancer cells and apoptotic bodies (1-3 µm) (Fig. 3). The main 
function of extracellular vesicles is to facilitate inter-cellular communication. This exchange 
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takes place in a pleiotropic manner. For example, the surface proteins from the donor cell can be 
transferred to recipient cell by membrane fusion and thus delivering respective contents such as 
transcription factors, oncogenes, small and large non-coding regulatory RNAs such as 
microRNAs (miRNAs), mRNAs. This transfer is crucial to maintain the physiological functions 
such as tissue repair, immune surveillance or blood coagulation.  In addition, it has recently been 
identified to play a role in the progression of diseases like cancer by especially being involved in 
the establishment of pre-metastatic niche43.  
 
              
Figure 3: The different types of extracellular vesicles secreted by different cells. Primarily based on their size 
exosomes (40-120 nm) and microvesicles (100-1000 nm), secreted as membrane blebs, are formed by all types of 
cells whereas apoptotic bodies are formed from dying cells. Oncosomes (1-10 µm) are secreted by cancerous cells 
by membrane blebbing. Adapted from44. 
 
1.5.1. Microvesicles 
                 MVs are extracellular membrane bound particles generated by all cell types which are 
found circulating in the blood, urine and other body fluids45,46. Rapidly proliferating cancer cells 
undergoing EMT also produce MVs. The plasma membrane of cells consists of an asymmetrical 
lipid bilayer showing the presence of phospholipids like phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) on the cytoplasmic membrane and phosphatidylcholine (PC) and 
sphingolipids on the exoplasmic membrane47. MVs are known to be highly pro-coagulant due to 
surface expression of negatively charged PS and the presence of tissue factor (TF), an important 
initiator protein of the blood coagulation cascade. The shedding of MV is a highly regulated 
procedure. The various functions of MVs are highly dependent on the type of cargo they carry 
which in turn depends on the cell where they originate. These particles can travel to distal areas 
away from their site of origin thus enabling horizontal transfer and deposition of bioactive 
molecules. For example, MVs from normal endothelial cells play a role in angiogenesis, those 
from skeletal cells initiate bone mineralisation and delivery of various proteins. Some proteins 
are selectively incorporated in the MVs such as Vesicle associated membrane protein (VAMP3), 
14 
 
Auxin response factors 6 (ARF6)- regulated proteins, Vascular Endothelial Growth Factor 
(VEGF), Fibroblast Growth Factor (FGF), Angiopoietin-1 and Ephrin A348.  
 
1.5.2. Large oncosomes (LO) 
                  The term large oncosomes was first used by J. Rak’s group to describe extracellular 
particles shed from glioma cells containing transferable EGFRvIII on their surface49. Following 
that, V.R. Minciacchi et al reported particles ranging from 1-10µm detected in the supernatants 
of prostate cancer cells. This was the first time the term large oncosomes was used, based on 
their atypical large size and cancer specific cargo43. Several studies have proven that highly 
aggressive and invasive tumour cells have a higher rate of oncosome production50,51. Especially, 
the cancer cell types undergoing a transition from the mesenchymal form to a more invasive and 
metastatic amoeboid phenotype, showed an increased production of LOs52. The exact distinction 
between MVs and LOs is still under investigation. LOs, like MVs, have been reported to carry 
miRNAs, metalloproteinases, GTPase, ADP-ribosylation factor 6, and caveolin-1. The only 
protein to be exclusively enriched in large EVs appears to be cytokeratin 18 (CK-18) which can 
be used as a potential marker to distinguish tumour-derived LOs from other EVs in tissues and 
plasma53.  
 
1.5.3. Role of EVs in metastasis 
               Tumour associated microvesicles (TMVs) have been reported to carry effectors which 
influence various pro-cancerous processes such as angiogenesis, ECM remodelling, 
immunoediting, transformation of normal cells, tumour invasion, establishment of pre-
metastatic niche and finally full-blown metastasis48. The host microenvironment evolves along 
with the progression of cancer which in-turn activates metastasis. Moreover, EVs have been 
studied extensively for their role in numerous types of cancers, especially in pancreatic cancer. 
For instance the involvement of exosomes in metastasis, especially pre-metastatic niche 
formation, is known and discussed extensively for some time now54. Exosomes have the 
potential to promote metastasis by activation of PI3K/AKT and MAPK signalling pathways, 
matrix-metallo proteinases 2 (MMP-2) and MMP-9, tyrosinase-related-protein-2 (TYRP-2) to 
mention a few55. Exosome-derived factors are actively taken-up by Kupffer cells to generate a 
fibrin-rich environment increasing the infiltration of tumour associated immune cells56. A few 
studies have also shown that pancreatic cancer-derived exosomes increased migration  and non-
adhesiveness of cells in vitro and were involved in pre-metastatic niche formation in the liver in 
vivo57. A high number of procoagulant MVs has been reported in pancreatic and breast cancer 
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patients58,52,59. The term oncosomes itself suggests that these particles are derived pre-
dominantly from cancerous cells and hence potentially play an important role in establishment 
of metastasis. Since LOs can be quantified not only in tissue surrounding the primary tumour 
but also in the blood, they could help to modify distal microenvironment thereby supporting 
metastasis51,53. In addition to prostate cancer, in a recent report, Headly et al. has been able to 
visualize, fragmentation of CTCs, that is large oncogenic fragments spontaneously being 
formed in the lung metastasis model60.  
 
1.6. Coagulation cascade 
      The coagulation cascade is a necessary process to maintain the integrity of the blood vessel. 
The process of blood clotting due to blood vessel injury and the subsequent dissolution of the 
thrombus and fibrinolysis following the repair of the injured vessel wall is termed haemostasis. 
The coagulation cascade is essentially a series of biochemical reactions involving conversion of 
a zymogen to the active enzyme ultimately leading to the conversion of soluble fibrinogen to 
insoluble fibrin (Fig. 4)61. The traditional classification of the pathway broadly comprises the 
intrinsic and the extrinsic (Tissue Factor (TF) dependent) pathways. The intrinsic pathway is 
initiated by surface-contact activation. An initiation complex comprising of high molecular 
weight kininogen (HK) is formed that converts pre-kallikrein into kallikrein. This initiation 
complex in-turn leads to the conversion of the zymogen Hageman factor (Factor XII) to the 
active enzyme FXIIa (Fig. 4)62. Further downstream, activated FXIIA converts FXI to FXIA 
leading to the activation of FIX to FIXa which is a member of the intrinsic tenase complex 
involved in the formation of activated FXa63,64. 
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Figure 4: A schematic diagram showing the coagulation cascade. The scheme shows the intrinsic pathway of 
blood coagulation (thick red arrows), the extrinsic pathway (thick grey arrows) and the common pathway (thick 
blue arrows). The respective feedback mechanisms are indicated by thinner arrows (blue and grey). Adapted 
from61. 
 
The extrinsic pathway triggers the formation of FXa due to exposure of TF as a consequence of 
vascular injury. TF immediately forms a complex with Factor VII to activate it. The TF-VIIa 
complex directly or indirectly activates Factor X. The formation of factor Xa triggers the 
downstream reactions leading to the formation of thrombin from prothrombin (common 
pathway) in the presence of Ca2+ ions and phospholipids, which in-turn leads to the conversion 
of insoluble fibrin to fibrin polymers (in presence of factor XIII). The resulting clot is formed 
by of fibrin polymers, platelets, red blood cells (RBCs) and/ or white blood cells (WBCs). The 
thrombin produced by the extrinsic pathway activates a positive feedback loop for the 
formation of factor Va and VIIIa which in turn accelerate the upstream production of Xa and 
IXa respectively62. 
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1.6.1. Cancer and coagulation 
                 The interdependency of cancer and coagulation has been known now for more than 
100 years. In 1865, Armand Trousseau for the first time described the clinical relation between 
thrombosis and cancer65. Cancer patients are susceptible to thrombosis and show several 
abnormalities related to haemostasis. An example is deep vein thrombosis (DVT) which is the 
second largest cause of death due to cancer progression66. The procoagulant activity of cancer 
cells is primarily thought to be responsible for the activation of blood coagulation during tumour 
development. It is particularly associated with haematogenous metastasis67. The expression of 
procoagulant factors on the surface of the cancer cells, like the expression of TF, may contribute 
to the recruitment of many immune cells and in the activation of platelet aggregation68. Most 
solid tumours in cancer patients and mouse models show presence of cross-linked fibrin69. In 
addition, fibrin degradation products might also aid pro-metastatic processes such as immune-
modulation and angiogenesis. The haematogenous, survival, spreading and arrest of cancer cells 
in the microvasculature is often associated with deposition of fibrin/ fibrinogen and platelets70. 
Taking in account all these facts fibrin might play a very important role in cancer development 
and metastasis. Therefore, it could be potentially exploited for diagnostic and therapeutic 
purposes involving early detection as well as prophylactic measures71. For example, fibrinogen 
and fibrin degradation products in numerous cancers can be used as therapeutic targets. In this 
context, it is important to know how anti-coagulant therapeutic regimes, which are extensively 
administered, affect metastasis development72,73,67. Indeed, the first line of treatment for 
coagulation-based complications (for e.g. venous thrombosis) usually involves administration of 
different anticoagulants. Some commonly administered anticoagulants are rivaroxaban, a direct 
FXa inhibitor and fondaparinux, a synthetic pentasaccharide which is an indirect FXa inhibitor. 
The lower-molecular-weight heparins such as enoxaparin and dalteparin have better 
antimetastatic effects in some cases than the widely popular warfarin a vitamin K antagonist74,75. 
 
1.6.2. Cell surface exposure of phosphatidylethanolamine (PE) 
                 As mentioned in section 1.5.1. lipid bilayers typically show a characteristic 
asymmetrical distribution of phospholipids across the inner and the outer membrane. PE and PS 
are enriched in the cytoplasmic membrane whereas PC and sphingolipid (SL) are concentrated in 
the exoplasmic membrane76 (Fig. 5). This asymmetry is maintained by a group of phospholipid 
transporters called the flippases which mainly transport lipids (mostly PS and to a lesser extent 
PE) from outer membrane to the inner membrane and the floppases which transport the 
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phospholipids (PC and SL) from the inner membrane to the outer membrane at the expense of 
energy from ATP hydrolysis77. 
                                         
Figure 5: The topological structure of the proteins of the P4-ATPase family comprising 10 transmembrane helices 
with the N- and C- terminal on the cytoplasmic side. The domains are indicated as follows: large cytoplasmic loop 
containing (A) actuator, (P) phosphorylation and (N) nucleotide binding sites. Adapted from78. 
 
The third class of phospholipid transporters comprises of scramblases that transport all kinds of 
lipids in both directions in an energy-independent manner. Cancer cells have been reported to 
show an elevated exposure of PS on their surface suggesting a dysregulation of flippases 
activity79. The ATP dependent flippases and floppases primarily belong to the P-type and ATP-
binding cassette (ABC) family of transporters80. P4- ATPase is one of the largest subtypes, 
present only in eukaryotes, of a large superfamily P-type ATPases which consists of 
evolutionarily conserved proteins. They typically consist of a membrane bound protein with ten 
transmembrane helices and a large cytoplasmic loop harbouring actuator (A), phosphorylation 
(P), nucleotide binding (N) domains (Fig. 5)78. The P4-ATPAses are involved in various 
physiological processes and deficiencies in these ATPases have been reported to cause liver 
diseases, neurological disorders, immunological complications and diabetes81. The importance of 
PE exposure, as a tumour promotive measure, is still under investigations. For instance, 
phosphatidylethanolamine-binding-proteins (PEBPs) are over expressed on the surface of breast 
cancer cells (also in ovarian and prostate cancer), and knocking down this gene in these cells, 
induced apoptosis and arrested cell growth by rendering the cells more susceptible to 
chemotherapeutics82. 
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2. Objectives of the study 
 
Several different molecular mechanisms influence the metastatic potential of pancreatic cancer 
cells. The study of the interplay between the pancreatic cancer cells, their extracellular vesicles 
and the intravascular microenvironment at the site of metastasis will be the main goal of this 
project. Therefore, the work of this project revolves around three highly interdependent aims. 
 
First, we aimed to examine the pro-coagulant properties of pancreatic cancer cells and their 
extracellular vesicles in the microcirculation of the liver, the major site of pancreatic cancer 
metastasis. In particular, the mechanisms enabling pancreatic cancer cells and their microvesicles 
to stimulate coagulation were examined.  
 
Second, we analysed the exact time line of microvascular fibrin formation as induced by 
pancreatic cancer cells and their extracellular vesicles to determine their possible role in liver 
metastasis. We particularly were interested in studying the structure of fibrin-rich thrombi using 
high-resolution microscopic techniques in various in vitro as well as in vivo set ups. 
 
Third, the immune surveillance mechanisms triggered upon administration of cancer cells and 
tumour extracellular vesicles were evaluated. Specifically, we wanted to understand the 
intravascular immune response to the arrival of tumour material at the metastatic sites. In 
addition, the different immune cells and their potential roles in the survival or elimination of 
cancer cells were identified by various techniques including intravital imaging of these tumour 
entities in the microcirculation. 
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3. Materials and Methods 
 
3.1.  Materials 
3.1.1. Equipment 
 
Items  Company, Type 
Balance MC1 LC 620 S Sartorius (Göttingen, D) 
Cell culture incubator  Köttermann 
Cell culture microscope  Carl Zeiss 
Count chamber Neubauer Improved Brand (Wertheim, D) 
Culture Hood  Heraeus 
Electrophoresis power supply  EPS600 Pharmacia 
Electrophoresis unit small Bio-Rad Mini-Protean II 
ELISA Reader Dynatech MR7000 Dynatech Laboratories 
Gel Doc system  Vilber Lourmat 
Heating mantle  Eppendorf 
Incubator (cell culture) Heraeus (Hanau, D) 
Lamin Air flow HLB 2472 Thermo Scientific (Braunschweig, D) 
Light microscope Axiovert 100 Zeiss (Jena, D) 
LSM 510 Meta  Zeiss (Jena, D) 
Mega centrifuge  Heraeus, Omnifuge 2.0 RS 
Micropipettes  Eppendorf (Hamburg, D) 
Multiphor II blotting device  Amersham Pharmacia Biotech 
Nano Drop Thermo Fisher Scientific 
pH meter  HANNA instruments HI 221 
Pipet boy Integra-Bioscience (Biebertal, D) 
Pipettes (5ml, 10ml) Omnilabs 
Sonicator Bransor  Boston Laboratory Equipment 
Thermocycler  Biozyme, MiniCyclerTM, MJResearch 
Thrombelastograph  RoTEG Dynabyte 
Vortexer Sartorius (Göttingen, D) 
Water bath Julabo U3 Julabo Labortechnik (Allentown, USA) 
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3.1.2. Antibodies 
 
Antibody Company Catalogue no. Concentration 
anti-CD31 (PECAM-1) Abcam ab28364 5 µg/ml 
anti-CD31 (M-20) Santa Cruz sc-1506 5 µg/ml 
anti-PECAM-1 (MEM-05) Santa Cruz sc-51691 5 µg/ml 
anti-CD335 (NKp46) Biolegend 137602 20 µg/ml 
anti-CD8 alpha Abcam ab25478 2 µg/ml 
anti-CX3CR1 Abcam ab8021 10 µg/ml 
anti-CX3CR1 Novus NBP1-76949 10 µg/ml 
anti-CYTOKERATIN 18 NEB 4846S 0.4 µg/ml 
anti-F4/80 AB [CI:A3-1] Abcam ab6640 10 µg/ml 
anti-Fibrin II beta WAK Chemie NYBT2G1 5 µg/ml 
anti-hTF American 
Diagnostica AMD 4509 
50 µg/ml 
anti-human IgG American 
Diagnostica 4508CJ 
50 µg/ml 
anti-Ly6C [ER-MP20] Abcam AB15627 5 µg/ml 
anti-Ly6G BD Pharmingen 551459 15 µg/ml 
anti-Mouse Alexa 488; 546; 594 Life/Thermo A11034 2 µg/ml 
anti-Rabbit Alexa488; 546; 594 
Life/Thermo 
A11034; A11035; 
A11037 
2 µg/ml 
anti-rat Alexa 488; 546; 594 
Life/Thermo 
A21208; A11081; 
A21211 
2 µg/ml 
anti-rat IgG-Dylight488 Abcam ab96887 2 µg/ml 
anti-rat IgG-Dylight550 Abcam ab96888 2 µg/ml 
Anti-stabillin II STB2 3.1  Kai Schledzewski  5 µg/ml 
Anti-TMEM16F Santacruz sc-136930X 50 µg/ml 
Mouse Anti-Biotin (PE) Biolegend  409003 0.2 µg/ml 
mouse IgG1, Isotype Control Life/Thermo MG100 50 µg/ml 
mouse IgG2a, Isotype Control Life/Thermo MG2A00 50 µg/ml 
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3.1.3. Kits 
Name Company 
Catalogue 
no. 
Antibody Labeling Kit Alexa488 Life/Thermo A-20181 
Antibody Labeling Kit, Alexa555 Life/Thermo A20187 
Click-it Plus TUNEL 488 Kit Thermo fisher scientific C10617 
QIAquick Gel Extraction Kit Qiagen 28704 
RevertAid First Strand cDNA Synthesis Kit Thermo fisher scientific  K1621  
 
3.1.4. Buffers 
Blocking buffer 
1x PBS 
0.1 % Tween 20 
2% / 5 % / 10% BSA (as per protocol) 
 
CaCl2 (Faktor Xa Formation; 50ml) 
225 mg CaCl2 .2H2O 
ddH2O  
 
Ca/Hepes (TEG)  
10 mM Hepes 
100 mM CaCl2,  
ddH2O, pH 7,4  
 
PBS (Phosphate Buffered Saline) (1L) 
8 g NaCl 
0.2 g KH2PO4 
1.42 g Na2HPO4.2H2O 
0.2 g KCl 
 
Permabilisation/ Blocking-Buffer 
0.2 % Fish Skin Gelatin 
0.5 % BSA 
0.1 % Saponin   
Sterile filtered 
 
Tris-EDTA buffer 
10 mM Tris pH 8.0 
1mM EDTA pH 8.0 
 
TNC (Tri-Nitrium Citrate for blood drawing) 
3.68 g TNC 
100 ml ddH2O 
Sterile filtered 
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10X Tris-Boric-EDTA Buffer (1 L) 
55 g Boric acid 
107.8 g Tris-HCl 
7.44 g Na-EDTA 
pH 8.3 
 
10X-SDS-PAGE running buffer (1 L) 
30.25 g Tris 
144 g Glycin 
50 ml 10% SDS 
 
Resuspension buffer (1 L) 
138 mM NaCl 
2.7 mM KCl 
12 mM NaHCO3 
0.4 mM NaH2PO4 
1 mM MgCl2.6H2O 
5 mM D-Glucose 
5 mM Hepes 
pH 7.35 
 
5X SDS-PAGE Sample buffer (10ml) 
1 ml 10X Tris-HCL (3.1 M pH 6.8) 
0.25 g SDS 
5 ml Glycerol 
12.5 mg Bromophenol blue 
6% (v/v) ß-Mercaptoethanol 
 
Tryphan Blue in PBS (cell counting) 
0.4% Tryphan blue 
1 mM Ca++ 
ddH20 
 
SDS-PAGE transfer buffer (1L) 
2.9 g Glycine 
5.8 g Tris 
100 ml Methanol 
3.7 ml 10% SDS 
 
Blocking buffer for WB membrane (1L) 
100 ml 10X TBS 
1 ml Tween 20 
50 g non-fat dry milk (BSA) 
900 ml distilled water 
Filter with 0.2 mm Whatmann filter paper 
 
Washing buffer for WB membrane (1L) 
100 ml 10X TBS 
3 ml Tween 20 
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3.1.5. Cell lines 
 
Type Origin  
KPC Mouse pancreatic cancer cell 
line 
Dr. Hana Algül, II. Medizinische Klinik 
und Poliklinik, Klinikum rechts der Isar der 
TU München (München)  
L3.6pl Human pancreatic cancer cell 
line 
Prof. Christiane Bruns, Klinik für 
Allgemein-, Viszeral- und Gefäßchirurgie, 
Otto-von-Guericke Universität 
(Magdeburg)  
PANC-1 Human pancreatic cancer cell 
line 
ATCC 
 
 
3.1.6. Mouse models 
Type, Name  
C57BL/6 M/F 21-25 G ca.8+ Weeks Charles River 
LysM+eGFP   
CX3CReGFP  
 
 
3.1.7. Chemicals 
Name Company Catalogue no. 
Acetone 99,5%  Carl Roth 9372.2 
Acrylamide bis-Acryl Sigma A3699 
Beriplex CSL Behring Apotheke 
Cell culture Flasks: 175cm2 straight neck  BD Pharmingen 353112 
Cell culture Flasks: 25cm2 straight neck  BD Pharmingen 353107 
Cell TrackerTM Red BODIPY Dye ThermoFisher Scientific C2102 
Cell TrackerTM Red CMTMR Dye ThermoFisher Scientific       C2927 
Cell TrackerTM Red CMTPX Dye ThermoFisher Scientific C34552 
Chromogenic Substrate S-2222  Haemochrom Diagnostic 41201 
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Control siRNA  Santa Cruz sc-37007 
Corn Trypsin Inhibitor (CTI) Calbiochem 650345 
DAKO Pen for immunohistochemistry Dako Cytomation S200230 
Desirudin (S.cerevisiae) AFl 15 mg Inresa REVASC  
DMSO Hybrid-Max Sigma D2650 
DNA Ladder 100BP Life/Thermo 15628050 
DNA Polymerase (Taq) New England Bioloabs M0273S 
     DNA polymerase (ampliTaq 360 gold) ThermoFisher Scientific 4398818 
dNTP Mix PCR grade Qiagen 201900 
DRAQ5 Abcam ab108410 
Duramycin Sigma D3168-10MG 
Duramycin-LC-Biotin Mol. Targeting Techn. D-1003 
Acetic acid Carl Roth 3738.1 
Ethanol 99.8%  Carl Roth K928.3 
Fibrinogen from hPlasma Sigma F3879-100mg 
FM 4-64 FX  Life/Thermo F34653 
Gelatin 2% Solution Sigma G1393-20ML 
Generuler 1 KB DNA-Ladder Fermentas SMO311 
HCl 37% Carl Roth 9277.1 
Kalium  hydroxid; Potassium hydroxide Carl Roth 3904.1 
Lipofectamine 2000 Reagent Life/Thermo 11668027 
Mayer´s Hematoxylin Science Service GmbH 26381-02 
Methanol >99.5% Carl Roth CP43.4 
Mucin1 shRNA Plasmid (h) Santa Cruz SC-35985-SH 
Multiwell plate: 12-well  BD Pharmingen 353225 
Multiwell plate: 24-well  BD Pharmingen 353226 
Multiwell plate: 6-well  Omnilab 353046 
Multiwell plate: 96-well BD Pharmingen 353072 
NaCl 1Kg Carl Roth P029.2 
NaOH Pellets Roth 041300 
Object glass slides SuperFrost Omnilab J1800AMNZ  
PBS Sigma D8537 
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Pipette, 10 ml Omnilab 4488 5380582 
Pipette, 5 ml Omnilab 4487 606180 
Poly-L-Lysine Solution Sigma P8920-100ML 
Protease Inhibitor  Roche 11206893001 
Protein Assay Reagent A BioRad 500-0113 
Protein Assay Reagent B  BioRad 500-0114 
Puromycin  VWR 540411-25MG 
RacGAP-1 siRNA (m) Santa Cruz SC-76336 
Reaction cups Safe-Lock (1.5 ml) Eppendorf 0030 125.193 
Reaction cups Safe-Lock (2 ml) Eppendorf 0030 120.094 
Roteg-Cuvettes (Cup and Pin pro) Rotem 200011 
siRNA negative control Qiagen  1027284 
Sodium Carbonate Anhydrate Sigma S7795-500G 
SYTO 62; SYTO 60; SYTOx-Green Life/Thermo S7020 
TEMED  Carl Roth 2367.3 
Thromborel S 400T Siemens Healthscare OUHP29 
Tissue Tek T-TEK Hartenstein TTEK 
Tween20 (Polyoxethylene) Sigma P1379-100ML 
Vecta-shield Hard Set with DAPI Linaris H-1500 
Vecta-shield with DAPI  Enzo/Life/Thermo 
VC-H-1200-
L010 
Water Tissue culture tested Sigma W3500-500ML 
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3.1.8. Cell Culture Reagents 
 
Name Company Catalogue no. 
DMEM 1 g/l Glucose Life/Thermo 31885-023 
DMEM 4.5 g/l Glucose Life/Thermo 41965-039 
FBS Life/Thermo 10270106 
Freezing Medium  Ibidi 80023 
MEM alpha Medium Life/Thermo 22571-020 
NEAA (100X) PAN Biotech P08-32100 
OPTI-MEM (1X) + L-Glucose. Life/Thermo 31985-047 
Penicillin/Streptomycin (100X) Invitrogen 15140-122 
RPMI 1640-Medium with L-Glutamine Life/Thermo 21875034 
Trypan Blue Carl Roth CN76.1 
Trypsin-EDTA Solution (10X) Sigma 59418C 
Vitamin (MEM-Vitamin Mix; 100X) Merck/Millipore K 0373 
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3.2. Methods 
3.2.1. Animal experimentation protocol 
                      All the mice mentioned in section 3.1.6 were obtained from Charles river and were 
kept under specific pathogen free conditions at the animal facility of Walter Brendel Centrum. 
The age group of the mice used for the all experiments ranged from 9 weeks to 14 weeks. All the 
animal experiments were performed as per the guidelines of the local legislation on protection of 
animals (Regierung von Oberbayern, Munich). Mouse blood was drawn intra-cardially after 
anesthetisation (isoflurane; Delta Select GmbH), fentanyl i.p. (0.05 mg/kg body weight; 
CuraMed Pharma GmbH), after which the mouse was sacrificed by strangulating the neck and 
subsequent the organs were collected and processed as described in section 3.2.4. 
 
3.2.2. Injection protocols 
                      The injection scheme for the animal experiments was as described in scheme 1. All 
the injections of the cancer cells and MVs were i.v. injections via the tail vein. MVs were always 
injected as two doses (75 µg each), with a gap of 10 min between the two doses. Cancer cells (2 
x 106 cells) were injected after 1 h of the second MV injection and the organs (liver, lung, 
kidney, and heart) and blood were collected after different time points like 0.5 h, 2 h, 6 h, 24 h, 
48 h. Scheme 1, part (i) shows the different points after either CMTPX-pre-labelled KPC cancer 
cells or KPC MVs injection. Long-term experiments were also performed with KPC cancer cells 
together with KPC MVs as described in scheme 1, part (ii), where the animals were sacrificed 
after 8 days or 14 days. The CMTPX-labelled MVs were injected first, 1 h after which the 
BODIPY labelled-cancer cells were injected. 
  
 
 
Scheme 1: Injection schemes for KPC cells (2x106) and KPC MVs (150 µg). All injections were made in the tail vein of 
the mice. i) only KPC cancer cells or KPC MVs pre-labelled with CMTPX were injected ii) CMTPX-labelled KPC 
MVs plus BODIPY-labelled KPC cancer cells were injected for long term experiments.  
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3.2.3. Administration of substances 
                      The effects of different substances affecting blood coagulation for e.g. 
anticoagulants, inhibitors on the various phenomenon like microvascular fibrin formation, 
microcirculatory arrest of tumour cells, killing of cancer material and extravasation was 
investigated. In order to achieve this, the mice were either pre-treated before injection of cancer 
cells and EVs or the cancer cells with EVs were pre-treated before being injected into the mice. 
The cancer cells and MVs were pre-treated with 10 µm duramycin, for 30 min at room 
temperature (RT) in a final volume of 100 µl. In order to wash of the duramycin, the cells and 
vesicles were then washed twice with PBS at 1300 rpm for 5 min and 12600 rpm for 30 min 
(without break), respectively. In case of biotin labelled duramycin the same procedure as 
mentioned before was used where the cells were coated with 10 µM biotin-labelled duramycin. 
To block the TF induced extrinsic pathway of coagulation, the cells and MVs were incubated 
with respective anti-TF antibodies (50 µg/ml mouse 1h1 anti-TF; or human anti-TF from 
American diagnostica) for 30 min at RT in a final volume of 100 µl. The antibody in the solution 
was washed away using PBS by centrifugation at 1300 rpm for 5 min. To block fibrin formation, 
the mice were administered with factor Xa inhibitor rivaroxaban (3 mg/kg body weight; i.v.) 4 h 
before the administration of MVs and/ or cancer cells. The effect of PCK, a factor XII inhibitor, 
was checked by injecting it at a concentration of 10 mg/kg body weight; i.v. few minutes right 
before the cancer cell and/ or MV injections.  
 
3.2.4. Preparation and storage of organs 
                     After organs such as liver, lung, spleen, kidney and heart were harvested from the 
animals, they were fixed in 2% formalin solution for 2 h. The fixed organs were then transferred 
to 30% sucrose solution and incubated overnight at 4 ˚C after which the organs were stored at -
80 ˚C. The sucrose fixation step was especially essential to preserve the GFP signal from pre-
labelled cells. 
 
3.2.5. Cryosections 
                      The organs were stored for at the least 24 h at -80 ˚C before being embedded in 
tissue-tek and subsequent sectioning. The organs were completely covered in tissue-tek to embed 
them fully at -20 ˚C in the cryotome. The organs were mounted on the apparatus to enable 
cutting. Sections ranging from 5 µm-10 µm were prepared. The sections were immediately 
collected on super-frost glass slides, which were pre-labelled with the respective animal number, 
treatment and other relevant information (time point, type of cell etc.). The slides were stored at -
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20 ˚C and remaining organs embedded in tissue-tek and were stored at -80 ˚C until required 
further to prepared fresh sections.  
 
3.2.6. Paraffin embedded section 
                   The organs for the paraffin embedding were first collected in plastic embedding 
cassettes and incubated overnight in 4% formalin. The cassettes containing the organs were 
then washed thoroughly (5-15 min) with distilled water. The organs were transferred to a 
container containing 70% ethanol and incubated for at least 24 h. Thereafter, the organs along 
with the cassettes were transferred to an embedding apparatus, which dehydrated them by 
dipping them in increasing concentrations of ethanol and were finally soaked in paraffin. After 
removing the dehydrated, paraffin soaked organs from the machine, the organs were manually 
embedded in paraffin at a pouring station to embed the organs in paraffin blocks which 
facilitates the sectioning of organs. The paraffin sections were made by means of a microtome. 
The organs were mounted onto the device and 4 μm thick sections were produced. To prevent 
wrinkles on the sections while cutting, the paraffin embedded organ slices were transferred to a 
water bath the temperature of which was maintained between 55-65 °C. The uniform sections 
floating on warm water were carefully transferred on super-frost glass slides. These slides were 
dried overnight at 37 °C in the drying cabinet and then stored at RT. 
 
3.2.7. Cell culture 
                      The KPC cell line was isolated from the pancreas of a genetically modified mouse, 
KPC (LSL-KRASG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre), which developed spontaneous 
metastasis. The mice carried a point mutation for KRAS (G12D) and p53 deletion mutant along 
with a Cre recombinase gene. This cell line was cultured in high glucose DMEM (4.5 g/l) with 
2.5% NEAA, 10% FBS and 1% penicillin/ streptomycin. The cell lines were passaged every 8-
10 days. The L3.6pl cell line is a human pancreatic cancer cell line which was generated by 
orthotropic implantation of human cancer cells into the mouse pancreas. This cell line was 
maintained in low glucose DMEM (1 g/l) with 10% FBS, 2.5% NEAA, 2.5% vitamins and 1% 
penicillin-streptomycin. The cell line was passaged every 10-12 days. The PANC-1 (ATCC) cell 
line, is another human pancreatic cancer cell line, was cultured in high glucose DMEM (4.5 g/l), 
10% FBS and 1% penicillin-streptomycin. The cell line was passaged every 8-10 days. All the 
cells were maintained in an incubator with relative humidity, 95%; carbon dioxide (CO2), 5%; 
temperature, 37 °C. The cells were grown in cell culture flasks of various sizes as per 
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requirement and maintained with an appropriate amount of culture medium as stated in the 
catalogue. 
 
3.2.8. Maintaining cell lines 
                   The cells were passaged using trysin-EDTA solution. The culture medium was 
removed and the flask was rinsed with PBS (1 ml-5 ml) to remove of remaining medium. 1 ml of 
trysin-EDTA solution was added to 175 cm2 flask; 0.5 ml to a 25 cm2 flask and incubated at 37 
°C until to allow cell detachment. Detached cells were collected in falcons followed by addition 
of 1-5 ml PBS. This step was performed twice followed by addition of 5-10 ml complete 
medium to the flasks to collect all the remaining cells. The cell suspension was centrifuged at 
1300 rpm for 5 min. The supernatant was discarded and the cell pellet was resuspended in ≈1 ml 
PBS/complete medium followed by addition of 10 ml PBS, this being the second wash step. The 
cells were centrifuged once again as mentioned above and resuspended in 1-2 ml PBS/complete 
medium. The cells were counted using a Neubauer chamber and further either cultivated in order 
to maintain them or used for the desired purposes. 
 
3.2.9. Preparation of cell stocks 
                      Stocks of cell lines were prepared of all cell lines and stored at -80 ˚C or liquid 
nitrogen. The cells were passaged as explained in section 3.2.8. Once the cells were washed by 
subjecting them to centrifugation twice at 1300 rpm for 5 min at RT each time, after which the 
cells were resuspended in 1 ml freezing medium (Ibdi) and stored at -80 ˚C or in liquid nitrogen.  
 
3.2.10. Transient transfection 
                   Cells were seeded in 6 well plates on the day before transfection, to attain a 
confluency of 50% - 80% at the time of transfection. The medium was removed and optiMEM 
medium was added and the suspension was incubated at 37 ˚C for 1 h. Cells were transfected 
using either of the following transfection reagents (Lipofectamine2000, RNAiMax, Ibdi 
Transfection reagent) according to the manufacturer’s protocol. The siRNA and the transfection 
reagent were diluted in optiMEM. siRNA mix was added to the transfection mix and the mixture 
was incubated for 30 – 45 min at RT to allow the formation of a complex of siRNA with 
liposomes. The optiMEM medium from the cells was removed and siRNA plus liposome 
mixture was added to the cells. The cells were incubated for 4 h-6 h at 37 ˚C to allow the 
internalisation of siRNA. Medium without antibiotics was added to the cells and incubated 
overnight without removal of the siRNA complex mixture. The medium was then replaced on 
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the following day. The transfection efficiency was checked by western blotting and functional 
assays 48 h/72 h after transfection. 
 
3.2.11. Stable transfection 
                   Stable transfection was performed using shRNA. The transfection techniques use the 
same protocol as described above (section 3.2.10.). After 48 h-72 h of transfection the selection 
of the transfected cells was started. This step facilitates the elimination of non-transfected cells. 
Based on the properties of the construct used for transfection of the cells, after transfection, the 
appropriate antibiotic (ampicillin, puromycin or gentamycin) was added for selection. In order to 
start the selection process, the cells were subjected to an increasing concentration of the 
antibiotic (for e.g. puromycin was added in a range between 3 µg/ml to 20 µg/ml) until no more 
dead cells were seen after at least 24 h of incubating with one particular concentration. The 
stably transfected cells were always cultured in media containing at least a basal concentration of 
the antibiotic used for selection (for. e.g. 10 µg/ml puromycin was used). 
 
3.2.12. Isolation of extracellular vesicles 
                   Two types of extracellular vesicles were isolated from the supernatants of cells or 
blood, MVs (ranging between 0.1 µm to 1 µm) and large oncosomes (ranging between 1 µm to 
10 µm). The isolation of the vesicles involved a series of centrifugation steps based on the size of 
the vesicles. The samples were subjected to initial centrifugation at 1300 rpm for 10 min 
(without break) to remove of large cells and debris. In order to isolate MVs the samples were 
then centrifuged at 4000 rpm for 20 min (without break) twice to eliminate large vesicles and 
remaining debris. Next the supernatant was subjected to a centrifugation step of 12600 rpm for 
30 min (without break) with a maximum volume of 750 µl in an Eppendorf cup. The pellets 
obtained after this centrifugation step were pooled and used for various experiments as required. 
Oncosomes were isolated with the help of vivaspin ultracentrifuge columns or purely 
centrifugation based techniques. The supernatant obtained after the initial centrifugation step at 
1300 rpm for 10 min was added to the top of the vivaspin columns (0.2 µm pore size; PES) and 
subjected to a short centrifugation step at 8000 g for 30 s. In case of the centrifugation based 
approach, the oncosomes were pelleted at 10,000 g for 30 min after the initial centrifugation step 
at 1300 rpm for 10 min with a maximum volume of 750 µl in the Eppendorf cups. The amount of 
vesicles was estimated as total protein content of the pellet. 
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3.2.13. Protein estimation 
                   The amount of protein present was estimated using Bradford’s assay which is an end 
point, chromogenic assay. The samples were resuspended in a minimum volume of 500 µl PBS. 
A 1:1 serial dilution ranging from 2 mg/ml to 0.03906 mg/ml was made using a standard protein 
solution of 2 mg/ml BSA. 5 µl of the standards and samples were added in triplicates to a 96-
well plate. 25 µl of copper-alkali-tartrate containing solution A, which forms a complex with the 
proteins in the suspension, was added to each well. 200 µl of solution B, which reduces the 
protein complex to generate blue colour from the previous yellow colour of the solution A, was 
added to each of the wells above. The absorbance was measured at 700 nm in a plate reader. The 
protein concentration of the samples was calculated from the standard curve using excel scatter 
graph format. 
 
3.2.14. Thromboelastography (TEG) 
                   TEG is a technique used to analyse the various parameters of thrombus formation in 
whole blood such as the clotting time (fibrin formation), clot strength and other parameters. The 
procoagulant activity of cancer cells, MVs or oncosomes was tested by this technique using 
whole blood as a medium. The assay was performed in a specialised TEG pin and cup apparatus. 
250 µl of the whole blood with 60 µl of a solution of 30mM CaCl2 with HEPES and 30 µl of 
sample suspension was added to each TEG cup. The measurements were made using a rotation 
thromboelastometry device from ROTEG. 
 
3.2.15. Factor Xa formation 
                       A chromogenic assay was used to measure the procoagulant activity of the extrinsic 
pathway of the blood coagulation cascade. Serial dilutions of the standard Thromborel-S were 
prepared. To each well of a 96-well plate 50 µl of 30 mM solution CaCl2 was added. To these wells 
50 µl of standard/samples were added. A master-mix of chromogenic substance S-2222, Beriplex 
and the respective amount of resuspension buffer was prepared such that 100 µl of this mix was 
pipetted per well. The absorption was measured at 405 nm using a plate reader (softMAXpro). A 
cycle of 6 min was repeated for a total of 36 min and the final values were expressed as milliunits 
(mU)/ ml. 
 
3.2.16. Preparation of phospholipid liposomes 
                   Liposomes containing different types of phospholipids were generated using PE, PS 
and PC (Avanti Polar lipid). For the preparation of the liposomes (100 mol% PC; 30 mol% PE, 
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70 mol% PC; 30 mol% PS, 70 mol% PC) the phospholipids were dissolved in 1 ml of 
chloroform. A film of lipids was generated on the walls of the glass tubes by purging with inert 
gas (nitrogen). To the phospholipids 2 ml PBS was added. To dispose the lipids sterile glass 
beads were added and the suspensions were rigorously vortexed. Then the suspensions were 
ultrasonicated for 5 min (40 W) in an ice-bath under inert conditions (continuous flow of 
nitrogen over the surface). The generated liposomes were pelleted by ultracentrifugation at 
100,000 g for 30 min. All the steps after the dissolution of the lipids were carried out at cold 
temperatures between +2 to +8 ˚C. 
 
3.2.17. Immunohistochemistry: Immunostaining of cryo-sections 
                   Immunohistostaining is a procedure to perform imaging by detecting specific 
antigens by selective antibodies. There are two methods of detection, direct immunostaining 
wherein the antigen is directly detected by a primary antibody coupled with a fluorophore and 
indirect immunostaining in which case the antigen is detected by a primary antibody, which is in 
turn detected by a secondary antibody coupled with a fluorophore.  
Cryosections (5-10 µm) were fixed using formalin (2%-4%) for 15 min at RT followed by 
subsequent washing thrice with PBS for 3 min each. In order to avoid unspecific binding of the 
primary antibody a blocking step with 2% BSA in PBS was performed for 1 h at RT. After 
washing once again, the primary antibody with appropriate dilutions was added to the sections 
and incubated overnight. To retain the primary antibody solution on the sections plastic 
coverslips were laid on the sections or each section was encircled with DAKO pen to restrict the 
antibody flowing out of the tissue section. Excess of primary antibody was washed away with 
PBS as mentioned above. The sections were then incubated with respective secondary antibody 
for 1 h at 4 ˚C. To stain the nucleus DAPI (1:5000 from stock) was added, after removing the 
secondary antibody solution, for 5 min at RT followed by subsequent washing with PBS thrice 
for 3 min each. The sections were then mounted with glycerol and sealed with nail polish or 
mounting medium. The analysis was performed using Confocal Laser Scanning Microscope 
(LSM510, Zeiss). 
 
3.2.18. Immunostaining of cells in suspension 
                   The cells were harvested and washed with PBS (1300 rpm for 5 min at RT) and 
counted in a Neubauer chamber with addition of trypan blue to identify dead cells. The viability 
of the cells was 90%-95%. Cell staining was performed in sterile Eppendorf cups. Usually 8x105 
the cells were resuspended in 100 µl PBS. The cells were fixed with 1% formalin for 10 min at 
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37 ˚C. 200 µl PBS was added to the cells and the cell suspension was centrifuged at 1300 rpm 
for 5 min. The supernatant was discarded and the cell pellet was resuspended in 300 µl PBS 
followed by centrifugation at 1300rpm for 5 min. The cells were resuspended in 200 µl PBS with 
2% BSA and an appropriate dilution of the antibody was added to the cell suspension. After 
incubating for 1 h-4 h at 37 ˚C with intermediate vortexing, 200 µl PBS was added to the cells 
and the suspension was centrifuged at 1300 rpm for 5 min to remove the unbound primary 
antibody. The cells were washed twice with 300 µl PBS by centrifugation. The appropriate 
secondary antibody was added at a concentration of 2 µg/ml which was diluted in PBS. The cell 
suspension with the secondary antibody was incubated for 1 h at 4 ˚C in the dark with 
intermediate vortexing. The excess secondary antibody was washed off by subjecting the cell 
suspension to centrifugation at 1300 rpm for 5 min thrice. The cells were stored in a 100 µl 
suspension with PBS in the dark until microscopic analysis. The immunostaining of the vesicles 
was performed with the same procedure as used for immunostaining of suspended cells. The 
washing steps for the EVs differed based on the type of particles. MVs were centrifuged at 
12,600 rpm for 30 min at RT whereas large oncosomes were centrifuged at 10,000 rpm for 30 
min at RT. 
 
3.2.19. Immunostaining of adherent cells 
                   The cells were grown the day before starting the staining procedure in 8-microwell 
plate or 24-well plate with sterile coverslips, as per the requirement, to attain maximum 70% 
confluency. The cells were washed thrice with sterile PBS (0.2-1 ml) briefly by pipetting or 
aspiration. The cells were blocked with 2% BSA for 20-30 min at 37 ºC followed by briefly 
washing them once with PBS. The primary antibody was added with appropriate dilution in 
0.5% BSA solution in PBS for 1 h at 37 ºC. After washing thrice with PBS as mentioned before 
the respective secondary antibody at a concentration of 2 µg/ml was added to the cells for 1 h at 
4 ºC. To stain the nucleus SYTO-green (5 µM) was added for 5 min along with FM 4-64Fx (1 
µg/ml) to stain the plasma membrane at RT. This was followed by fixing the cells with 1% 
formalin for 10 min at RT. The stained cells were then washed thrice with PBS to remove extra 
formalin. The cells were stored at 4 ºC in PBS until imaging. If the cells were to be stained with 
SYTOX-green or DAPI these nuclear stains were added after the fixation with formalin because 
these dyes stain the nucleus of dead cells or cells with perforated outer membrane. 
 
 
      
36 
 
3.2.20. Staining with long lived fluorophore 
                   The MVs and cancer cells were stained with long lived fluorophores called 
CellTrackerTM dyes CMTPX (red), CMTMR (orange) or BODIPY (green). These different dyes 
were used to label the cells and MVs with the required fluorophore as per the experimental 
design. The staining was performed as per the guidelines provided by the company. The required 
numbers of cells or MVs were suspended in 200 µl of PBS. A working solution with a 
concentration of 40 µM of the dyes, from pre-diluted stock of 10 mM, was prepared in PBS and 
pre-warmed for 10-30 min at 37 ˚C. To each probe 200 µl of prewarmed working solution of the 
dye was added such that the final concentration used for staining was 20 µM. This sample was 
gently mixed by pipetting or vortexing and incubated at 37 ˚C for 10-30 min. The stained sample 
was subjected to centrifugation to remove the dye in the solution at 1300 rpm for 5 min for cell 
staining and 12600 rpm for the MVs or 10000 rpm for the oncosomes for 30 min at RT (without 
break). These steps were repeated once again to wash the sample thoroughly, with 200 µl of PBS 
as a final wash step. To check if the staining was successful, an aliquot of the stained sample was 
checked by fluorescent microscopy before injection. 
 
3.2.21. TUNEL staining 
                   The killing of cancer cells was calculated by analysing the apoptotic index. The 
apoptotic index accounts for the number of dead cells plus the number of apoptotic bodies as 
compared to the total number of cells. In order to identify dead cells and other dead material 
TUNEL staining (terminal deoxynucleotidyl transferase dUTP nick end labelling) was 
performed. The principle of the protocol is based on the use of a highly purified TdT enzyme 
that incorporates fluorophore conjugated nucleotides at the 3'-hydroxyl termini of DNA double 
strand breaks that are usually generated in the DNA of dying cells. Here for the TUNEL staining 
the Click-it Plus TUNEL 488 Kit was used (Thermofisher Scientific). Cryosections of livers 
from mice injected with pre-labelled (long-lived fluorophore) cancer cells or MVs were treated 
exactly as per the protocol provided by the manufacturer. The TUNEL positive cells were 
identified by the co-labelling of the cells/vesicles with the long-lived fluorophores 
(CMTPX/CMTMR), TUNEL staining (green) and DAPI. A cell showing these three labels was 
considered as dead cell (≥ 5 µm). Dead cancer material for e.g. apoptotic bodies were identified 
in a similar way by the co-labelling of long lived fluorophore (CMTPX/ CMTMR), signal from 
TUNEL staining (green) and with but without staining positive for DAPI. These entities largely 
represented particles smaller than 5 µm. 
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3.2.22. Haematoxylin and eosin staining for paraffin sections 
                   This procedure was performed to visualise cluster of abnormal cells in paraffin 
sections of liver tissues. Initially glass slides with paraffin sections were prepared (refer to 
section 3.2.6). To facilitate the staining of the organ sections the slides were first de-paraffinized 
by incubating them in ROTICLEAR for 3 min at RT under the hood. Thereafter, the hydration of 
the tissue was performed by subjecting the section to a series of decreasing concentrations of 
ethanol solution in distilled water. The sections were incubated twice in 100% ethanol for 5 min 
at RT, while intermittently shaking the slides. This was followed by dipping the slides once in 
96% ethanol for 2 min at RT and then in 70% ethanol for 2 min to complete the re-hydration of 
the tissues. The tissue sections were then stained with Mayer’s hemalum solution 
(Merck)/Haematoxylin solution for 5-6 min and washed by rinsing at least 3-4 times with 
distilled water. In order to rinse the slides thoroughly and accentuate the staining, slides were 
washed with distilled water for 10 min with intermittent shaking followed by washing the slides 
with distilled water once for 10 min. The slides were then briefly washed in 70% ethanol to 
improve the eosin staining. Next, the tissue sections were stained in eosin solution for 5-6 min. 
The tissues were then dehydrated again to fix them. Next, the slides were first briefly dipped in 
distilled water, followed by immersing the slides in ethanol of increasing concentration i.e. 70%, 
96% and 100% (in this sequence) and then finally briefly in ROTICLEAR to dehydrate them 
completely. The slides were briefly rinsed in 100% ethanol before mounting the sections in 
glycerol. 
 
3.2.23. Immunohistochemical image analyses 
                   The analysis of immunohistochemically treated samples was performed using 
confocal laser scanning microscopy. The Zeiss 510-CLSM system was used with argon lasers to 
generate lower wavelength light beams and a combination of three helium-neon lasers for 
wavelengths above 500 nm. The image analysis was based on the use of various versions of the 
ZEN software (Blue 2009/ 2011; Black 2012; Lite 2.3). 
 
3.2.24. Two-photon imaging 
                   Intra-vital imaging was used as a method to image the injected cancer cells pre-
labelled with CMTPX/ CMTMR/ BODIPY and EVs pre-labelled with CMTMR/CMTPX in the 
intra- and extravascular compartments of the mouse liver. The mouse liver was imaged using a 
multiphoton LaVision Biotech (Bielefeld, Germany) TrimScope II system connected to an 
upright Olympus microscope, equipped with a Ti:Sa Chameleon Ultra II laser (Coherent) 
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tuneable in the range of 680 to 1080 nm. Additionally, an OPO (optical parametric oscillator) 
compact supported the range of 1000 to 1600 nm. The system is equipped with a 16X water 
immersion objective (numerical aperture 0.8, Nikon). Single images were acquired from a range 
80 μm to 100 μm in depth of the liver tissue along with a z-interval of 2 μm. 820 nm was used as 
an excitation wavelength, with 1024×1024 pixels and detected by photo multiplier tubes (G6780-
20, Hamamatsu Photonics, Hamamatsu, Japan). ImSpector Pro (LaVision) was used as 
acquisition software.  An environmental box maintained a stable 37°C environment.  
To facilitate the visualisation of vesicles/cancer cells they were pre-stained with long-lived 
fluorophore (section 3.2.18.). The blood flow was visualised by injecting FITC-Dextran (low 
molecular weight 10 KDa) or Blue- Dextran (50-100 µg/ml) in a final volume of 200 µl in PBS 
into the tail vein of the mice. The mice were anaesthetized by isoflurane (Delta Select GmbH) 
and fentanyl i.p. (0.05 mg/kg body weight; CuraMed Pharma GmbH) and mounted on a custom-
built stage connected to a vacuum ring pump device to image the liver for the detection of pre-
labelled MVs or cancer cells. In order to restrict the severity of surgery only a small incision to 
the abdominal cavity was made to expose the liver lobes. The anaesthesia was applied 
intraperitoneally every 35 min during the entire time of imaging as a reduced dose (1/3 of the 
afore-mentioned dose). The imaging was performed after various time points, usually after 2 h,  
4 h, 6 h, or 24 h.  
 
3.2.25. Scanning electron microscopy: Preparation of samples 
                   Scanning electron microscopy was performed to image and identify the structures of 
the fibrin network along the vessel walls of the microvasculature in the mouse liver. The liver 
samples of animals previously injection with cancer cells alone or with cancer cells plus MVs 
were analysed. The liver tissue was fixed in 2.5% GAD for a minimum of 48 h. The sections of 
the liver were made using the vibratome. In order to mount the liver tissue onto the vibratome, 
the fixed tissue was embedded in the 4% agar in PBS using a single well of a 24-well plate as a 
cast. The block of agar with the tissue was mounted onto the vibratome. Sections of the size 
ranging from 100 µm – 200 µm were made with a blade frequency of 200 vibrations/min. The 
sections were immediately transferred in PBS and stored at 4 ˚C until they were prepared further 
for analysis by scanning electron microscopy. 
 
3.2.26. Immuno-fluoro-gold labelling for detection of fibrin fibres 
                   The liver tissue was fixed in a mixture of 2% formaldehyde + 1% GAD overnight at 
4 °C. The tissue sections were then washed thrice for 5 min each in PBS+glycin (50 µM) with 
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continuous shaking. Blocking was performed in 2% bovine serum albumin (BSA) solution in 
PBS to avoid unspecific binding of the antibody followed by washing, thrice, for 5 min in PBS 
with 0.2% BSA. Rabbit anti-Fibrinogen primary antibody prepared in PBS with 0.2% BSA 
(Dako; 1:300) and added for 1 h at RT followed by subsequent washing for 5 min, 10 min and 15 
min with 0.2% BSA in PBS. The first secondary antibody an anti-rabbit Nano gold-antibody 
diluted in 0.2% BSA in PBS (1:100) was added for 30 min followed by a single wash step for 
5min with 0.2% BSA in PBS. The second secondary antibody, anti-rabbit Alexa 488-labelled 
antibody (2 µg/ml) was then added for 1 h at 4 °C. The sections were washed for 5 min, 10 min 
and 15 min with PBS. Bright field images were acquired using different magnifications with the 
help of the Zeiss LSM510 and fluorescence was detected by the 488 laser. Areas of interest were 
marked for subsequent analysis and identification by scanning electron microscopy.  
 
3.2.27. In vitro fibrin clot analysis by scanning electron microscopy 
              The scanning electron microscopic experiments were performed to take a closer look at 
the differences in the various properties of clot formation induced by cancer cells as well as host 
cells (monocytes). The fibrin-rich clots were generated using 25 µl platelet poor plasma, 50 µl of 
Alexa 488-labelled fibrinogen (1 mg/ml) and 25 µl of sample solution containing 2000/5000 
cancer cells/ monocytes. The clotting reacting was started by adding 30 µl of a 20 mM CaCl2 
solution and the reaction was stopped after different time points (0, 2, 10, 30, 45, 75 and 105 
min) with the use of formalin solution with final concentration of 2% in the reaction mixture. C-
LSM analysis of the clot was done to visualise the clot and obtain the parameters to calculate its 
density. The fixed clot was also processed to be imaged by scanning electron microscopy at 
Helmholtz Zentrum Muenchen (Abteilung Analytische Pathologie; Dr. Michaela Aichler, AG 
Walch). The density was calculated by measuring the intensity profile by ZEN 2009 software. 
For each image, the number of fibres intersecting with a line of 50 µm length were analysed by 
accounting for the number of intensity peaks per line. A similar line in an area with no fibres was 
used as blank. The average of the values of the intersecting peaks was used to determine the 
density of the fibrin-rich clot.  
 
3.2.28. Labelling of primary antibody 
              Primary antibodies raised in mice were labelled with Alexafluor-mAb labelling kit to 
avoid signals due to unspecific binding of secondary antibody. In co-staining procedures, to 
facilitate the use of two antibodies raised in the same animal, only one primary-labelled antibody 
was used. The labelling was performed as per the instructions in the manual. Anti-fibrin, anti-
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stab2, anti-CX3CR1, anti-Ly6G, anti-Ly6C primary antibodies were labelled with the kit. The 
general procedure required 50-100 µg of antibody which was incubated with the labelling 
reagent for 3 h at RT or overnight at 4 ˚C. To remove the extra dye in the solution the labelled 
antibody was recovered using Zeba spin columns equilibrated with appropriate buffer as per the 
instructions of the manufacturer. 
 
1.1.1.  Statistical analysis 
                    All the values are represented as mean values. Error bars represent standard error of 
the mean (SEM) The significance was calculated using the Sigma-Stat software and the results 
were analysed by one-way ANOVA, Mann-Whitney ranks test or unpaired t-tests. Differences in 
the mean values with p<0.05 were considered to be as statistically significant. 
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4. Results 
4.1. Expression of TF in pancreatic cancer cells 
         The pancreatic cancer cell lines used for the experiments were immunostained to examine 
the expression of the coagulation initiator protein, TF. The two cell lines used were L3.6pl, a 
human pancreatic cancer line, and KPC, a mouse pancreatic cancer cell line (section 3.2.7). The 
cells were stained with the appropriate anti-TF antibody (anti-mTF antibody or anti-hTF 
antibody) and the respective Alexa-546-labelled secondary antibody as explained in section 
3.2.17. The cell membrane was identified by staining with the FM-64Fx dye and the nucleus was 
stained with SYTO-Green at the end of the staining procedure. The cells were then fixed with 
1% PFA to facilitate imaging via C-LSM. The image in Fig. 6a shows that the human pancreatic 
cancer cell line L3.6pl strongly expresses TF (orange dotted structures) on the surface of the 
cells. In contrast, the mouse pancreatic cancer cell line KPC meagrely expressed TF on the 
surface of the cells (Fig. 6b).  
 
 
Figure 6: a) L3.6pl cells stained with anti-hTF antibody (50 µg/ml; American Diagnostica) and respective Alexa 
546-secondary antibody. b) KPC cells stained with anti-mouseTF antibody (50 µg/ml) and respective Alexa 546-
secondary antibody (orange). The cell membrane was stained with FM-64Fx dye (red) and the nucleus with SYTO-
Green. Scale bars: 10 µm. 
 
Therefore, it can be hypothesised that the pro-coagulant activity of L3.6pl cell line might be 
attributed to the surface expression of TF. In contrast the pro-coagulant activity of KPC cells 
could potentially be due to expression of other pro-coagulant factors on the cell surface. 
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4.2. Procoagulant activities of pancreatic cancer cells 
4.2.1. In vitro analysis 
                  As a next step to test our first hypothesis, to investigate the procoagulant activity of 
the cancer cells, functional in vitro assays were performed. The activation of Factor X, indicating 
the activation of a central element in the coagulation cascade, was monitored by a chromogenic 
assay. This chromogenic assay requires the use of S-2222 as substrate to test the extent of 
formation of Factor Xa (section 3.2.17). L3.6pl cells and KPC cells were tested for FXa 
formation under different conditions.  
 
Figure 7: Factor Xa formation with cancer cells. The cells were pre-treated with anti-hTF or anti-mouse1h1 
antibodies or appropriate isotype antibody, duramycin (10 µM) or respective vehicle controls. Experiments were 
performed with 10,000 cancer cells per experiments and the data represents the standard error mean of at least three 
experiments per condition. * p < 0.05; ** p <0.01; *** p < 0.001. 
 
In particular the neutralisation of TF by anti-TF antibody and the effects upon pre-treatment with 
duramycin and rivaroxaban was tested (Fig. 7). Duramycin is a cyclic peptide which specifically 
binds to PE exposed on the outer membrane of lipid bilayers. The L3.6pl cells stimulated Factor 
Xa formation to a higher degree than the KPC cells (comparison between Fig. 7a and 7b). The 
Factor Xa formation by L3.6pl cells was reduced upon pre-treatment with anti-TF antibody. In 
contrast, no change in Factor X activation was seen after incubation of KPC cells with anti-mTF 
antibody. This was in accordance with our previous results, indicating that L3.6pl expressed TF 
on their surface to a much higher extent than the KPC cells (Fig. 6). After treatment with 
duramycin (10 µm) the Factor X activation of both cell types was strongly reduced (Fig. 7a and 
b). This indicated that the PE exposure on the plasma membrane played an important role in 
triggering the pro-coagulant activity of the pancreatic cancer cells under investigated (Fig. 7a 
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and b). Similarly, pre-treatment with rivaroxaban also showed similar results with decrease in 
stimulation of FXa formation. 
 
4.2.2. Scanning electron microscopic analysis of fibrin fibres in vitro 
                   The structure of the fibrin fibres and the overall composition of the fibrin network 
were further studied by in vitro methods. The fibrin clot was generated in vitro in the 
presence/absence of KPC/L3.6pl cancer cells and as a control, by host immune cells (LPS-
activated monocytes). To this purpose cancer cells were added to a mixture of labelled 
fibrinogen and platelet-poor plasma. The clot density, the branching of the fibres and their 
diameter were analysed as explained in section 3.2.27. Overall the cancer cells formed the clot 
much faster than the clot generated by the activated monocytes (data not shown). Nevertheless, it 
was observed that the density of the clot formed by the cancer cells (Fig. 8a and b) appeared not 
to be strongly different from the one formed by the activated monocytes (Fig. 8c). The images 
shown below are indicative of a clear association of the fibrin clot with the cancer cell. In 
addition, the cancer cell also shows some membrane blebs and EVs in its vicinity.  
 
                    
Figure 8: Scanning electron microscopic images of fibrin clots generated in vitro as explained in section 3.2.27. (a) 
Clot generated by L3.6pl cell. (b) Figure inset was magnified to view the cancer cell and the membrane blebbing. 
(C) Fibrin clot generated by LPS stimulated inflammatory monocytes isolated from human blood samples.  
Scale bar 5 µm. 
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4.2.3. Release of EVs by pancreatic cancer cells                   
                   The different pancreatic cancer cell lines were tested for oncosome production. The 
supernatant of KPC and L3.6pl cells was processed for isolation of oncosomes as described in 
section 3.2.12. The cancer cells were stained with membrane markers (diL 550) and nuclear 
marker (Syto-62). The oncosomes in this case were detected as spherical membrane blebs of 
varying sizes at the surface of the cancer cells. These blebs likely represented large oncosomes 
did not contain any traces of nuclear material and the boundaries of the vesicles were marked by 
membrane markers (Fig. 9). The particles ranged from a size of 2 µm – 7 µm.  
 
 
Figure 9: Oncosome production in vitro. a) KPC cells and b) L3.6pl cells in suspension showing production of 
EVs with characteristic of large oncosomes. The membrane was marked by DiL-550 dye which also stained the 
membrane blebs. Scale bar 10 µm. 
The release of EVs, especially oncosomes was also analysed in other pancreatic cancer cell lines 
too. The extent of oncosome production was analysed as a total protein content of oncosomes 
which were isolated from the supernatants of different cell lines. Six cell lines with different 
genotypes were analysed, three of which were isolated from metastatic pancreatic tumours and 
three from non-metastatic pancreatic tumours. The metastatic cell lines that were used are as 
follows: 5320 that contained a p48-Cre promoter which is specific for pancreatic cancer, KRAS 
mutation (G12D) by knock-in in the endogenous locus under the control of a stop cassette Lox-
Stop-Lox (LSL) along with a reporter gene PCNA followed by an internal ribosome entry site 
(IRES) (p48-Cre +/-, LSL-KRAS+/-, LSL-PCNA-IRES +/-); number 53631, which had a p48-
Cre promoter with KRAS mutation (G12D) (p48-Cre+/-, LSL-KRAS+/-), and cell line S134 
which contained a Pdx-Flp  promoter with KRAS mutation (G12D) under the control of Flox-
Stop-Flox (FLF) stop cassette with (Pdx-Flp +/+, FSF-KRAS +/-). The non-metastatic cell lines 
used were 8182, which had a p48-Cre promoter and a KRAS mutation (G12D) under the control 
of a stop cassette LSL along with a reporter gene allele Tva (p48-Cre +/-, LSL-KRAS +/-, Tva 
+/+); number 5671 that contained a p48-Cre promoter and a KRAS mutation (G12D) along with 
two reporter gene allele Tva and PCNA-ATG all under the control of a stop cassette LSL(p48-
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Cre +/-, LSL-PCNA-ATG +/-, LSL-Tva +/-, LSL-KRAS +/-) and number 16990 which had the 
same genotype as cell line number 53631(p48-Cre+/-, LSL-KRAS+/-). The oncosomes from the 
supernatant of a confluent layer of respective cell lines were isolated as described in section 
3.2.12 and were estimated as a total protein content of the oncosome pellet (section 3.2.13.). The 
metastatic cell lines showed on an average increased production (0.052 µg/ml) of oncosomes 
accounting to almost double the amount as compared to the average production (0.024 µg/ml) by 
the non-metastatic cell lines. Nevertheless, one of the non-metastatic cell lines (16990) was seen 
to produce an amount of oncosomes close to one of the metastatic-cell lines (0.047 µg/ml) which 
may be attributed to the similarity in genotype to the metastatic cell line 53631. Therefore, these 
results indicate that the production of oncosomes might be dependent on the metastatic potential 
of these cell lines. 
4.2.4. Visualisation of PE exposure in vitro  
            
Figure 10: Shows the exposure of PE on the surface of a) unstimulated monocyte b) KPC cancer cell and c) KPC-
MUC1 cancer cells. The PE expression was visualised by biotin-labelled duramycin and recognised by anti-biotin 
secondary antibody as described in section 3.2.16. The pre-coating of cancer cells with biotin labelled duramycin 
was performed as mentioned in section 3.2.3. followed by immune-staining. A) The monocyte showed reduced PE 
exposure. b) The KPC cancer cells showed a stronger membrane staining of PE whereas (c) the MUC1 
downregulated cell showed a reduced staining of PE on the surface. Scale bar: 10 µm. 
 
The surface exposure of PE was examined by immunostaining procedures as described in section 
3.2.18. in both, KPC cells as well as in KPC-MUC-1 downregulated cells. We have seen that 
downregulation of MUC-1 in KPC cells reduced the procoagulant activity of the cells (data not 
shown) and therefore might affect the surface exposure PE, especially in the TF-independent 
mechanism. In the control cells i.e. the unstimulated monocytes a very weak exposure of PE was 
detected. Whereas the KPC cancer cells, it was seen that PE was distributed over the entire 
surface of the KPC cells in a rather punctate pattern (Fig.10a). In contrast, PE exposure was 
strongly reduced in case of the KPC cell with reduced MUC-1 expression (Fig. 10b). Therefore, 
downregulation of MUC-1 reduced the surface exposure of PE. This in turn might be responsible 
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for the reduced pro-coagulant activity of the cells with reduced MUC-1 expression seen in our 
previous work. 
To investigate this aspect further the exposure of PE was also analysed via a functional assay by 
employing artificially synthesised liposomes and MVs. The liposomes containing PE+PC, 
PE+PS or PC (control) were synthesised as explained in section 3.2.16. Functional assays like 
chromogenic assay evaluating the FXa stimulation and TEG were performed (Fig. 11).  
         
 
 
Figure 11: a) and b) Factor Xa formation assay conducted with L3.6pl MVs and different liposomes as indicated 
below each bar without duramycin (vehicle control) or with duramycin, respectively. c) and d) TEG with whole 
blood along with L3.6pl MVs and different liposomes as indicated below each bar without duramycin (vehicle 
control) or with duramycin, respectively. n=3 mean values +/- SEM. *** p<0.001; n.s. non-significant. 
 
Highly pro-coagulant L3.6pl MVs were incubated with the liposomes either with or without 
duramycin. It had already been shown in figure 7a, that duramycin significantly reduced the 
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procoagulant activity of the MVs. Figure 11b shows that the activation of FXa formation was 
reduced in the case where MVs and PC+PS or PC containing liposomes were treated with 
duramycin. In the case of PC+PE containing liposomes and MVs with duramycin the factor Xa 
formation was partially activated. The clotting time was also reduced. Both, these results suggest 
that under the conditions analysed duramycin specifically binds to PE. 
 
4.3. Bio-informatics analysis of genes involved in phospholipid translocation 
         The role of altered surface exposure of PE in tumour cells was studied further by 
examining for potential mutations in genes involved in the translocation of phospholipids across 
the plasma membrane. First, the exposure of candidate proteins involved in phospholipid 
transport like ATP11C, TMEM16J and TMEM16F was downregulated by means of siRNA. 
Anti-TMEM16F antibody was also used to block this protein. Functional analysis by TEG 
indicated no significant changes in the clotting time under all conditions (Fig. 12). 
 
Figure 12: KPC cells were transiently transfected with siRNAs for a) ATP11C b) TMEM 16J c) TMEM16F and d) 
anti-TMEM16F antibody. The clotting time was analysed by TEG. n=3 mean values +/- SEM. n.s.: not significant. 
 
Therefore, to broaden the search for potential candidate genes the online database, The Cancer 
Genome Atlas (TCGA) were used to screen for the occurrence of possible mutations in 
pancreatic cancer patients. This database contains information from various ongoing genomic 
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sequencing projects on pancreatic carcinoma. Genes hypothesised to be involved in phospholipid 
translocation like P4-ATPases, phosphatidylethanolamine binding proteins (PEBP), anoctamins 
to mention a few, were included in a list of a test group of 141 genes. A list of entries carrying 
mutation in any of the 141 genes was compiled and analysed by bioinformatics tools to extract 
those genes which showed maximum frequency of mutations. The pool of samples contained 
178 tumour samples which were compared amongst each other for differences in their protein 
expression profiles of the genes. Out of the 141 genes, 89 genes were chosen based on the 
analysis that more than 50% of the samples reported mutations in these 89 genes. After 
normalising the genes so that they are nearly in the same range (c-score normalisation) the 
differences in the expression pattern were represented as a heat map. In the Fig. 13 each row 
represents the protein expression data from a single gene and each column represents a single 
sample (i.e. data from a single patient).  
      
Figure 13: Heat map of protein expression profiles of pancreatic cancer patients (horizontal axis) vs the protein 
expression profiles of each gene (vertical axis). Each entry on the horizontal axis corresponds to each patient and the 
vertical axis shows each gene. Blue: indicates low expressed genes; red: highly expressed genes.  
 
The data set was organised such that patient entries and protein expression data of the genes with 
similar profiles are clustered together. The colour key with the histogram of the data set is shown 
in the top left corner of Fig. 13 where blue represents low expression of proteins and red 
represents high expression of the respective protein. The patches (dark red) represent highly 
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expressed genes in patients. After co-relating each gene from different clusters with the 
frequency of mutation no significant relation was seen. Nevertheless, TP53 was seen to be 
mutated maximally followed by APOB, DYNC1H1 and ATP10A. Most of the mutations were 
substitute-missense mutations. Another database COSMIC, was also used to analyse the same 
group of genes to check for the frequency of mutation. As expected the maximum number of 
mutations occurred in TP53. This was followed by the P4-ATPase ATP8A2 and the P4-ATPase 
ATP10A which ranked third in this list. Furthermore, upon analysing a subset of the data, we 
searched for the location of the mutations in the various domains of the P4-ATPases. This sub-
set revealed that most of the mutations were present in the cytoplasmic domain close to the 
phosphorylation and nucleotide binding sites of the protein. Since phosphorylation and protein 
binding sites are essential for the normal functioning of the protein, mutations in these domains 
are likely to impair its physiological functions and hence to reduce the transfer of phospholipids 
such as PE to the inner leaflet of the cell. 
 
4.4. In vivo analysis of microvascular fibrin formation                                                           
        The hypothesis that the cancer cells and their MVs support the activation of blood 
coagulation in vivo was investigated further. To pursue this, the pancreatic cancer cells (2 x 106) 
and MVs (150µg) were injected intravenously via the tail vein in WT mice.  
                                 
Figure 14: Graphical representation of the fibrin-covered area in the microvasculature a) after KPC MV injection b) 
KPC cell injection after different time points c) after L3.6pl MV injection d) L3.6pl cell injection after different time 
points respectively (section 3.2.20). Fibrin covered area was measured encircling the fibrin stained area (stained 
with primary-labelled anti-fibrin antibody) of the total intravascular area (measured by encircling the vessels stained 
with anti-Stab2 antibody). The Zen2.3 lite- blue edition program was used to make the calculation. Each bar 
represents a mean + SEM from n=3. * p < 0.05. 
50 
 
 
Subsequently, the fibrin-covered area was measured in the blood vessels of the liver at different 
time points after administration of the MVs or cells. The injections were made as per the 
schemes described in section 3.2.2. The fibrin-covered area was calculated as the percentage of 
intravascular area covered by fibrin in liver microvessels as labelled with anti-stab2 antibody, a 
specific marker of sinusoidal endothelial cells.  
 
     
Figure 15: Immuno-histochemical analysis of mouse liver tissue. The mice were injected with KPC cancer cells and 
were liver samples were analysed after a) 2 h, b) 6 h, and c) 24 h after the injection so as to determine the extent of 
microvascular fibrin formation. The vessels were stained with anti-stab2 antibody (red) and anti-fibrin antibody 
(green). Scale bar: 5 µm. 
 
As depicted in Fig. 14a and b fibrin formation was already evident after 2 h of cancer cells’ 
injection or their MVs. In case of both, KPC cells and their MVs, the peak of fibrin formation 
was observed at 6 h (Fig. 14a and b). The fibrin-formation area was lower at 24 h (Fig. 14a and 
b), which could be a consequence of fibrinolysis. A similar analysis was also done for the L3.6pl 
cells and their MVs. Similar to what has been observed with KPC cells, it was also observed that 
the fibrin formation was higher at 6 h as compared to 2 h (Fig. 14c and d). This indicated that 
fibrin formation reached a maximum at 6 h, which persisted for a while, and then a reduction in 
the fibrin formed was detected. Fig. 15 shows IHC images of microvascular fibrin formation in 
the mouse liver induced after 2 h, 6 h, and 24 h of KPC cancer cell injections, respectively. 
 
4.5. Fibrin fibre imaging by scanning electron microscope (SEM) 
4.5.1.   In vivo analysis 
                    Based on the results indicating that pancreatic cancer cells and their MVs induced 
fibrin formation in their liver microvasculature, further structural characterisation of the fibrin- 
rich aggregates was performed. WT animals were intravenously injected with cancer cells or 
cancer cells plus their MVs and the liver tissue was harvested 6 h after the injection. Vibratome 
sections of liver tissue were fixed in 2.5 % GAD and prepared for analysis by scanning electron 
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microscopy. The vessels which were exposed on the surface of the thick vibratome sections were 
more closely inspected. Microvessels with diameters ranging between 5 µm and 30 µm were 
analysed to detect the presence of fibrin network (Fig. 16a). The inset Fig. 16b shows a 
magnified portion of the microvessel where it was seen that the fibrin fibres were attached 
closely to the vessel wall. The small openings like structures seen on the wall of the vessels 
represent fenestrations. Fig. 17a shows a vessel with a diameter of approximately 30 µm that 
contains a fibrin clot attached to the wall of the vessel. The figure inset clearly shows that the 
clot is a dense structure composed of fibrin fibres together with RBCs (recognised by their size 
and concave surfaces with saucer like morphology), leukocytes (recognised by their size and cell 
extensions) and platelets (detected by their size and irregular surface) along with some type of 
vesicles. Similar fibrin fibres forming a network over the vessel wall entrapping blood cells 
could also be seen in Fig. 17b. This indicated that the vessel walls of liver microvessels were 
indeed covered with fibrin (along with blood cells) as shown by the immune-histochemical 
analysis in Fig. 15.  
       
Figure 16: a) The figure shows a liver microvessel (10-12 µm) with fenestrations. The figure inset (b) on the right 
magnifies the vessel wall covered with single fibrin fibres (indicated with black arrows). The liver tissue was 
prepared as explained in section 3.2.25. The animal was injected with KPC MVs + KPC cells and the liver was 
harvested 6 h after injection. The liver tissue was fixed in 2.5% GAD for 2 h and SEM imaging was performed. 
Scale bar: 10 µm. 
 
a) 
b) 
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Figure 17: Liver microvessel with a fibrin-rich clot on the vessel wall. This WT mouse was injected with KPC MVs 
+ KPC cells and the liver was harvested 6 h after injection. Single fibrin fibres spanning the vessel wall form a loose 
network (indicated by black arrows). The liver tissue was fixed in 2.5% GAD for 24 h and SEM imaging was 
performed. Scale bars: 10 µm. 
 
Microvascular occlusion due to fibrin-rich clots formation was also detected in the sections (Fig. 
18). Fig. 18a shows a vessel that is occluded by a fibrin-containing thrombus. The clot is mostly 
composed of RBCs, leukocytes, platelets and vesicles. It appears that the fibrin network is 
needed to hold the clot together. A part of the clot was viewed under higher magnification to 
clearly visualise the fibrin network and the different cell types (Fig. 18b). Thus, these results 
suggest that the presence of intravascular tumour cells and their MVs induce the formation of 
fibrin- and RBC-rich microthrombi in the liver microvessels. 
      
Figure 18: a) Liver microvessel occluded by fibrin clot consisting of RBCs, leukocytes and platelets. The figure 
inset is magnified (b) to show a part of the clot. The animal was injected with KPC MVs + KPC cells and the liver 
was harvested 6h after injection. The liver tissue was fixed in 2.5% GAD for 24h and SEM imaging was performed. 
Scale bars: 5 µm. 
  
 
a) 
b) 
b) 
a) 
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4.5.2. Immuno-fluoro-gold labelling of fibrin fibres in vivo 
                   The fibrin fibres generated by tumour cells in vivo were analysed further. The liver 
sections from mice injected with KPC cancer cells and harvested 6 h after injection were tested 
for the presence of microvascular fibrin by immune-histochemical procedures before being 
processed for analysis by scanning electron microscopy. Vibratome-sections of mice livers were 
stained with primary anti-fibrinogen antibody. The organs were fixed with a mixture of 2% PFA 
and 1% GAD before immunogold-staining to facilitate parallel analysis by CLSM along with 
scanning electron microscopy. The staining was performed as per the protocol stated in section 
3.2.26. The staining with anti-rabbit Nano-gold particles was performed to confirm that the 
fibres detected were indeed fibrin. The fibres were seen to be closely attached to the vessel wall 
(Fig. 19a). The areas indicated with blue arrows in Fig. 19b clearly show Nano-gold particles on 
the fibres, confirming that the fibres seen in all the scanning electron microscopy images were 
fibrin fibres. 
 
 
Figure 19: Scanning electron microscopic image of a vessel wall showing a fibrin fibre in the liver microvasculature. 
a) Shows the structure of the fibres. b) Shows the same fibre to reveal the signal from the nano-gold particles (white 
bright spots on the fibre). The mouse was injected with KPC cells and the liver was harvested 6 h after injection, 
fixed with a mixture of GAD and PFA (described in section 3.2.25.). Scale bar: 5 µm. 
 
4.6.  Extravasation of tumour cells and tumour MVs in vivo 
4.6.1. Intra- vs extravascular localisation of cancer cells and their MVs 
                   The extravasation of MVs from KPC cancer cell line was determined by analysing 
the localisation of pre-stained MVs (by CMTPX dye) with respect to their localisation being 
intravascular or extravascular. MVs were injected in WT mice as described in section 3.2.2. 
where the pre-stained MVs were injected via the tail vein followed by IHC analysis. The liver 
microvessels were identified by staining the sinusoidal endothelial cells (SEC) with anti-Stab2 
b) a) 
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antibody. Extravascular MVs were already detected after 6 h of injection of MVs (Fig. 20). 
Within 48 h 95% of the tumour MVs were detected in the extravascular tissue (Fig. 20).  
 
       
Figure 20: Localisation of tumour MVs labelled with CMTPX detected in the microcirculation of the liver. Shows 
the analysis of MVs per visual field as an average of 10 visual fields. Results are mean + SEM. Each bar in the 
graph represents results from 3 independent experiments. * p < 0.05; n.s. not significant. 
 
Further, the extravasation of the cancer cells was studied in the liver microvasculature. Pre-
labelled KPC cells, following their injection into WT mice (section 3.2.2.) were detected in the 
mouse livers, both in the intravascular and extravascular compartments. The extravasation of the 
cancer cells begins to appear at 6 h and continued until 48 h (Fig. 21 a-d). In order to further 
follow the fate of the cancer cells in the tissue, long-term experiments with CMTPX-labelled 
KPC cells were performed. Thus, the localisation of the cancer cells was determined after 8 and 
14 days (Fig. 21e and f) of injection. After 14 days all cancer cells were detected to be localised 
in the tissue (Fig. 21f).  
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Figure 21: The intra- vs extravascular localisation of KPC cancer cells in the liver microcirculation 2 h to 14 days 
after administration of CMTPX (red) pre-labelled KPC cells into WT mice (section 3.2.2.). The localisation of the 
CMTPX-labelled cells in the intravascular vs extravascular compartment of liver tissue. The vascular compartments 
were identified by staining the SECs with anti-stab2 antibody. a), b), c) d), e) and f) represent graphs after 2 h, 6 h, 
24 h, 48 h, 8 days and 14 days of cell injection, respectively. Results are mean +/- SEM of at least n=3. * p < 0.05; 
** p < 0.01. 
 
4.6.2. Tracking of cancer cells by intravital 2-photon microscopy 
                   2-photon live imaging technique was implemented to track the movements of the 
pre-labelled cancer cells in the liver microvessels. The imaging was performed as mentioned in 
section 3.2.24. KPC cells pre-labeled with CMTPX were injected into the WT mice and blood 
flow in the vessels was visualised using FITC-dextran. Intravital imaging was performed over a 
continuous range of time periods beginning from 2 h to 4 h or from 5 h to 9 h after cancer cell 
injection. It was observed that the cancer cells were already arrested in microvessels at 6 h (Fig. 
22). It was also observed that the cancer cells appeared to cause a ‘stop’ in the blood perfusion 
(as depicted by the vessel marked by yellow dotted line in Fig. 22d).  
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Figure 22: A series of images showing the blood flow 6 h after injection of KPC cells pre-labeled with CMTPX. The 
blood flow in the liver microcirculation was detected with FITC dextran. The area outlined by yellow dotted lines 
indicates the area of stop flow, where cancer cells (red) are seen to be arrested. Panels a), b), c), and d) correspond to 
6 h, 6.5 h, 7 h, and 7.5 h respectively. Refer to video 1 in section 6. Scale bar: 50 µm. 
 
This obstruction in the blood flow was not seen at the earlier time points until 4 h. Interestingly, 
as shown in Fig. 23 microvessel outlined in yellow where no reduction or stop in the flow was 
detected. Particularly the Fig. 23a and 23b corresponding to increasing time 2 h and 2.5 h 
respectively (imaging period 2 h-4 h), no indications of reduction in the blood flow was 
observed. However, during the same time period the cancer cells were seen to be arrested in the 
microvessels already at 2 h post injection.  
      
Figure 23: The series of figures showing the blood flow starting 2 h after KPC cell injection (pre-labelled with 
CMTPX). The blood flow in the microvessels was detected with FITC dextran. The yellow dotted line marks a 
microvessel. Pre-labelled cancer cell arrested in this vessel could also be clearly seen (red). Panels a), b), c), and d) 
correspond to 2 h, 2.5 h, 3 h, and 4.5 h respectively. Refer to video 2 in section 6. Scale bar: 50µm. 
 
During the live imaging between time period from 6 h to 9 h, near the area of flow-stop, 
extravasation of cancer cells in the liver tissue was seen 6 h after injection of pre-labelled cancer 
cells. One such representative example for cancer cell extravasation is shown in Fig. 24. The 
encircled area highlights a single cancer cell which was first arrested in the microcirculation 
(Fig. 24a) was seen to move out from the vessel (Fig. 24b - d) and to travel further within the 
perivascular tissue (Fig. 24f - h).  
 a)                                   b)                                c)                                  d) 
a)                                 b)                                   c)                                  d) 
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Figure 24: Series of images showing extravasation of a single cancer cell between 6 h-7 h. The KPC cells were 
injected in LysM+eGFP-labelled mouse and the liver was imaged by 2-photon microscopy. The blood flow was 
visualised by blue dextran. The panels (a)-(h) show images from the video with increase in time from a) 5.5 h; b) 6 
h; c) 6.5 h; d) 7 h; e) 7.5 h; f) 8 h; g)8.5 h; h) 9 h. Refer to video 3 section 6. Scale bar: 50 µm. 
 
4.7.  Immuno-histochemical analysis of EVs 
4.7.1. Co-localisation of MVs 
                   Cancer cells are known to secrete MVs in addition to large vesicles. The MVs were 
isolated from tumour cell supernatants (section 3.2.12.). The MVs were pre-labelled with 
CMTPX (red) and were injected in WT mice as described in section 3.2.2. To address our third 
hypothesis, we analysed the localisation of the MVs and their association with the immune cells. 
It was seen that the MVs were engulfed by host cells staining positive for the expression of F4-
80 in close proximity to sinusoidal endothelial cells. These results indicated that the MVs 
strongly associated with the immobilised macrophages of the liver microcirculation (Kupffer 
cells). Fig. 25a indeed shows MV inside Kupffer cells. The quantification of the association of 
MVs with macrophages in Fig. 25b shows that 95% of MVs are already associated with Kupffer 
cells 6 h after MV injection. 
a)                                b)                                  c)                                  d) 
e)                                f)                                 g)                                    h) 
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Figure 25: a) Shows KPC MVs (CMTPX) engulfed by macrophages (green) in the liver tissue 6 h after MV 
injection. b) The graph represents the percentage of MVs, detected in a visual field, that were engulfed by 
macrophages. Scale bar: 10 µm. n=3; Mean+/- SEM. *** p < 0.001. 
 
4.7.2. Intravital visualisation of the release of tumour EVs  
                       The release of EVs from pancreatic cancer cells in vivo was tracked by 2-photon 
microscopy. LysM+eGFP-labelled mice were injected with KPC cells pre-labeled with the long-
lived fluorophore CMTPX. The imaging was performed beginning from 5 h after the injection 
until 9 h. During the imaging phase between 7 h to 8 h after injection, the release of a large EV 
most likely signifying a large oncosome was observed (Fig. 26). The large vesicle was secreted 
by cancer cells previously arrested in the microcirculation. Fig. 26 shows a series of images 
captured over a 30 min duration wherein the release of a large vesicle was detected (encircled in 
white). An oncosome is released by the cluster of arrested cancer cells and eventually moves 
away from the cancer cells (comparison between Fig. 26a and Fig. 26d). Both, the oncosome 
which was released and an approaching LysM+GFP-labelled cell are indicated by a dotted circle 
(Fig. 26a - c). Furthermore, the released oncosome was immediately seen to be engulfed by a 
LysM+GFP-labelled cell (Fig. 26e and f). The LysM+GFP-labelled cell which engulfs the 
oncosome was seen to travel away from the arrested cancer cells (Fig. 26h - m). A crude path 
from the release of the oncosome followed by engulfment by LysM+GFP-labelled cell has been 
marked by a white dotted arrow in Fig. 26n.  
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Figure 26: Series of images showing the release of oncosomes from arrested cancer cells (blue arrow in panel a) 
and immediate engulfment by LysM+GFP-labelled cells. Figures a) shows the point of the oncosome was released 
(blue arrow) and LysM+GFP-labelled cell (lower dotted circle) which engulfs the oncosome. b) and c) show 
release of the oncosome. d) oncosome in contact with the LysM+GFP-labelled cell. e) the encircled area now-
onwards marks the oncosome which is completely engulfed. (f) the LysM+GFP-labelled cell which has engulfed 
the oncosome starts to move away from the cancer cell cluster. g) to m) show further transport of the engulfed 
oncosome. The entire path of release until where it was transported is marked by a dotted arrow in figure panel n. 
Refer to video 4 in section 6. Scale bar: 50 µm. 
 
4.8. SEM analysis of EVs in vivo 
       The localisation and interaction of the EVs inside the liver microvessels was further studied 
by SEM analysis. The mouse liver tissue was analysed 6 h after the injection of KPC cells and 
MVs. The tissues were fixed in 2.5% GAD as explained in section 3.2.25. It could be seen that 
the EVs closely interacted with immune cells (Fig. 27a). Indeed, it was observed that an 
extracellular vesicle (approximate diameter 3 µm) was engulfed by an immune cell (Fig. 27b). 
a)                               b)                              c)                               d) 
e)                               f)                               g)                              h) 
i)                                j)                               k)                               l) 
m)                              n) 
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The immune cells were a part of a larger aggregate consisting of EVs, RBCs, leukocytes and 
fibrin (Fig. 27c). The fibrin fibres appeared to be in close association to the vesicles.  
 
Figure 27: a) The SEM picture shows a microvessel which is occluded by EVs, fibrin and leukocytes. The inset 
which is magnified as figure (b) shows the part of the microvessel in which the EVs is being engulfed by the 
leukocyte. The magnified inset figure (c) shows EVs which have an overall size ranging from 2 µm-3 µm. Some 
EVs are seen to interact with fibrin fibres. Scale bar: 10 µm. 
 
4.9. Immune cell recruitment upon tumour cell administration 
4.9.1.  Immunohistochemical analysis 
                    The recruitment of the host immune cells during and after the arrest of KPC cells in 
the liver microcirculation was analysed. Particularly the identity of the immune cells recruited to 
the cancer cells and MVs in the liver microcirculation was identified. Overall 6 different immune 
cell types including NK cells, CD8+ T cells, CD4+ T cells, patrolling monocytes, inflammatory 
monocytes and neutrophils were identified with cell-specific antigens as marker (see section 
3.1.2.). The first cells to arrive in the microcirculation in substantial numbers (at 0.5 h) were NK 
cells as well as CD8+ T cells and CD4+ T cells. After 2 h, these cells reached a peak (Fig. 28a 
and Fig. 28b respectively). Recruitment of CD8+ T cells steeply declined after 6 h. Inflammatory 
monocytes (Fig. 28d) and neutrophils (Fig. 28f) showed an opposite recruitment behaviour. The 
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former was seen to be decreased with time, while the latter increased within 6 h. Patrolling 
monocytes only appeared after 6 h (Fig. 28e). 
 
           
 
Figure 28: Time dependent recruitment of immune cells in the liver microvasculature of WT mice injected with 
KPC cancer cells. The graph shows the number of cells per visual fields deduced from an average of 10 visual 
fields. The y-axis indicates the number of cells and the x-axis indicates the time point at which the mouse liver was 
harvested after the injection of cancer cells into the mouse. Each column represents the mean of three individual 
animal experiments with error bars indicating SEM. * p <0.05; ** p < 0.01; *** p <0.001. 
62 
 
4.9.2. Intravital imaging for immune cell recruitment 
                   The recruitment of neutrophils and their interactions with the cancer cells was further 
investigated by 2-photon live imaging using the LysM+eGFP-labelled mouse as described in 
section 3.2.20. In these mice, myeloid cells mostly representing neutrophils are labelled with 
GFP. In parallel the cancer cells were labelled with CMTPX and the blood flow was visualised 
by blue dextran. We observed that the GFP-labelled cells interacted extensively with cancer 
material (Fig. 29). They were seen to infiltrate the liver starting 4 h after KPC cell injection and 
the number of cells steadily increased until 7.5h (end of imaging shown in Fig. 29c).  
      
Figure 29: Infiltration of the liver microcirculation by LysM+GFP-labelled cells. Recruitment of myeloid cells 
strongly increases with time. The figure panels show the images of liver tissue after a) 5.5 h, b) 6.5 h and c) 7.5 h of 
injection of CMTPX labelled KPC cancer cells. Scale bar: 50 µm. 
 
Moreover, the LysM+GFP-labelled cell formed dense clusters around cancer cell material which, 
in some instances, were internalised by them (Fig. 30a). However, cell clusters were not 
engulfed the myeloid cells (Fig. 30b). 
                                
Figure 30: LysM+GFP-labelled cells interacting with cancer cells. a) Shows a cancer cell material completely 
engulfed by the LysM+GFP-labelled cells forming large clusters (indicated by arrows). b) Large cluster of cancer 
cells (indicated by arrows) not engulfed by LysM+GFP-labelled cells. Scale bar: 50 µm. 
 
 
 
a)                                              b)                                               c)                                    
a)                                          b) 
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In addition to the mouse model with GFP-tagged myeloid cells, mice with CX3CR1-GFP- 
tagged cells were used to investigate the interaction of tumour EVs with CX3CR1+ cells 
(including in particular labelled-patrolling monocytes). 
 
Figure 31: CX3CR1-GFP-labelled cell encircled to visualise its motion along the vessel wall. The GFP- labelled 
cell contained cancer material (red dots). CX3CR1eGFP mouse was injected with KPC cells labelled with 
CMTPX and the liver was imaged 6 h after injection. a) The GFP-labelled cell engulfing the EV (CMTPX) in the 
top of the dotted elliptical shape. b) to e) The cell is seen to travel further downward as marked by the yellow 
arrow in (d) and (e). g) The GFP-labelled cell has moved further down (centre of the elliptical shape). l) the white 
arrow indicates the path the GFP-labelled cell traversed. Yellow arrows indicate the position of the GFP-labelled 
cell. Refer to video 5 in section 6. Scale bar: 50 µm 
 
As shown in the Fig. 31, the CX3CR1-GFP tagged cells appeared to engulf small-sized cancer 
cell material (red), potentially EV and is seen to crawl along the vessel wall (the path of its 
movement is marked by a white arrow Fig 31l). Immuno-histochemical analysis of the same 
liver tissue showed clearly the engulfment of EVs by CX3CR1-GFP labelled cells (Fig. 32). The 
white arrows indicate EVs engulfed by GFP-labelled CX3CR1 cells. 
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Figure 32: CX3CR1-GFP labelled cell engulfing cancerous EVs (red). Arrows indicate the separate EVs which have 
been taken up by the GFP labelled cells. Nuclear staining was done by DAPI (blue). Liver tissue was analysed by 
indirect immunofluorescence technique as explained in section 3.2.1. Scale bar: 10 µm. 
 
4.10. Visualisation of cancer cell killing 
            The apoptotic index, a measure for dead cancer cells, was calculated by accounting for 
TUNEL stained tumour cells and apoptotic bodies (section 3.2.19.). Dead cancer cells were 
identified by co-labelling of CMTPX with TUNEL staining and DAPI. Fig. 33(a) shows a TUNEL 
and CMTPX-positive cancer cell that is additionally positive for DAPI.  
         
 
 
Figure 33: a) Dead cancer cells analysed by TUNEL staining. The cell shows a nucleus (DAPI), cancer cell staining 
(red) and TUNEL staining (green). b) Quantification of the apoptotic index where the number of dead cancer cells 
and apoptotic bodies is expressed as the percentage of the total number of cancer cells after KPC cell injection. c) 
Apoptotic index at 2 h of KPC cell injection after NK cell depletion by NK1.1 antibody as explained in section 
2.7.8. n=3, mean values ± SEM. Scale bar: 10 µm. 
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The apoptotic index was calculated as the sum of dead cancer cells and their apoptotic bodies 
and expressed as a percentage of total cancer cells. The latter were identified as being TUNEL, 
CMTPX positive and DAPI negative with a size ranging from 1 µm-5 µm. The apoptotic index 
was checked after 2 h and after 6 h cancer cell injection. It was seen that the apoptotic index was 
maximum at 2 h after cell injection (Fig. 33b). The killing of the cancer cells could be a 
consequence of the attack by the NK cells, specifically since the NK cells are recruited to 
arrested cancer cells (see Fig. 28a). Therefore, the apoptotic index was also checked after NK 
cell depletion. The depletion was performed by injection of NK1.1 antibody (blocking antibody) 
intravenously. NK cell depletion led to a decrease in the apoptotic index (Fig. 33c). This 
suggested that the elimination of the cancer cells was partly mediated by the NK cells. 
 
4.11. Long-term experiments 
4.11.1.  Detection of micro-metastasis 
                    To study the formation of micro-metastasis long term experiments were performed 
to test the hypothesis that MVs assist in the establishment of pre-metastatic niche. The liver 
tissues were analysed by H&E staining (refer to section 3.2.22) to identify the micro-metastatic 
structures. Transgenic mice were injected with KPC MVs (9x200 µg) i.v. over a period of 3 
weeks (3 times/ week). Paraffin sections of the mouse liver from five such mice were available. 
87% of the cell clusters had a size of <100 µm (Fig. 34a) whereas 6.5% had areas with sizes 
between 100-200 µm (Fig. 34b) and remaining 6.5% formed areas with sizes >200 µm (Fig.34c). 
The control mice did not show presence of any structures such abnormal structures. 
 
Figure 34: KPC mice were injected with a dose of 9x200 µg KPC MVs over a period of 3 weeks. HandE staining 
was performed to identify cell clusters in the liver tissue. a) representative picture of a cell cluster with a size of 
<100 µm; b) representative picture showing a cell cluster with a size range between 100-200 µm; c) representative 
picture showing a cell cluster with a size of >200 µm. Black circles: indicate the area of close cell clustering 
indicative of micro-metastasis formation. n=5. Scale bar: 100 µm. 
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4.11.2. Formation of micrometastatic foci with tumour cells and their MVs 
            In further studies, the fate of the tumour cells and their MVs in the mouse liver tissue 
was analysed. 8 days after injection of cancer cell (BODIPY) and their MVs (CMTPX), it 
was seen that the MVs had been engulfed by a host cell (based on their proximity to a 
nucleus), but did not seem to cluster with cancer cells (Fig. 35a). Instead after 14 days of 
injection the MVs and cancer cells could be seen to form clusters. Although such events 
were not frequently detected in the liver tissue, they could be indicative of the beginning of 
the formation of a pre-metastatic niche. 
 
Figure 35: WT mice were injected with BODIPY-labelled KPC cells plus CMTPX-labelled KPC-MVs and 
analysed after a) 8 days or b) 14 days. The tissue was analysed for localisation of the cancer cells and their 
MVs. The red arrows indicate MVs and yellow arrows indicate cancer cells. Scale bar: 10 µm. 
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5. Discussion 
     The role of pancreatic cancer cells and their EVs in establishing a pre-metastatic niche is 
highly dependent on the various cancer-derived and host-derived factors83. Firstly, the 
involvement of pancreatic cancer cells and their EVs in promoting blood coagulation was 
studied. The procoagulant activity was investigated based on the expression of TF which is the 
initiator protein of fibrin formation on various pancreatic cancer cell lines. The human pancreatic 
cancer cell line L3.6pl, showed a strong expression of TF on the plasma membrane. Whereas 
KPC cells, mouse pancreatic cancer cells derived from a transgenic KPC mouse model with a 
point mutation in the KRAS gene (G12D) as well as a p53 deletion under the control of the Cre 
promoter, showed almost no expression of TF on the plasma membrane. Further investigations 
were conducted to understand the relevance of these findings in a functional context. L3.6pl cells 
stimulated the formation of Factor Xa in a TF dependent manner as evidenced by neutralisation 
with anti-TF antibody which was seen to reduce the FX activation. The pro-coagulant activity of 
KPC cells was due to unknown pro-coagulant factors. These cells stimulated Factor X activation 
without the involvement of TF as seen from the FXa formation assay. Involvement of 
phospholipids in activation of FX is now known for more than a decade84,62 and given the role of 
the aminophospholipids85, the exposure of PE on the cell surface of the tumour cells was studied. 
Pre-treatment of both cancer cell types with the cyclic peptide duramycin,, markedly decreased 
FXa formation thus, supporting the hypothesis that the pro-coagulant activity of these cells could 
depend on an altered exposure of PE on the surface of the cells. The specificity of duramycin 
was determined by functional assays using amino-phospholipid containing liposomes which 
showed that duramycin specifically bound, in the experimental conditions applied, to PE but not 
to the other aminophospholipids. 
 
An altered exposure of PE on the surface of cancer cells and their MVs has been reported for 
instance in case of breast cancer cells PE. It has been postulated that PE potentially plays a 
pivotal role in recruitment of certain membrane-proteins84. Surface exposure of PE was also seen 
to increase in tumour vascular endothelium especially under hypoxic conditions85. Therefore, we 
hypothesised that the increased PE exposure of the cancer cells was due to the mutations in the 
genes that translocate phospholipids between the outer and the inner leaflet of the plasma 
membrane. Several different proteins control the surface exposure of PE, in particular the P4-
ATPases, PEBP, anoctamins and some adlo-keto reductases80,78. First, a few known candidates 
like the P4-ATPases ATP11C as well as scramblases like TMEM16J and TMEM16F were 
down-regulated by specific siRNA in pancreatic cancer cell lines. No significant change in the 
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pro-coagulant activity was seen after suppressing the expression of these proteins. Therefore, we 
performed a wider search was conducted for which we performed a bio-informatic analysis to 
screen online databases reporting information on the gene mutations in pancreatic cancer 
patients. Overall, we found several mutations in the genes potentially involved in phospholipid 
transport. The genes which most frequently showed mutations in these patients, apart from TP53, 
were DYNC1H1, APOB and ATP10a. In addition, another database search revealed slightly 
different results but confirmed ATP8A2 as a frequently mutated gene together with ATP10A. Our 
hypothesis was that the pro-coagulant activity of the cancer cells could be due to an increased 
constitutive exposure of PE on the outer leaflet of the plasma membrane. This could be a 
consequence of functional impairment of P4-ATPases (flippases) which maintain the asymmetric 
distribution of PE and PS by especially transporting the PE to the inner surface. In P4-ATPases 
ATP8A2 and ATP10A most of the mutations detected were present in cytoplasmic loop which 
harbours the ATP binding and phosphorylation domains. This hints towards the possibility that 
such mutations could render the flippases dysfunctional which would lead to a constitutive 
exposure of PE on the outer surface of the cancer cells. Additional results such as the expression 
profiles of these genes will be needed in future to obtain a more complete understanding of their 
role in the increased PE exposure in pancreatic cancer cells. 
The role of cancer cells as activators of blood coagulation was further studied under in vivo 
conditions. In particular the microvascular fibrin formation was analysed in the liver, which is 
the main site of pancreatic cancer metastasis. We observed substantial fibrin formation in the 
microvessels due to the pro-coagulant activity of the cancer cells and their EVs. One of the 
consequences of intravascular fibrin formation was the occlusion of microvessels by fibrin clots. 
This occlusion was observed to an extent which could contribute significantly to a ‘stop’ in the 
vessel perfusion. The microvascular fibrin formation observed in response to the arrest of cancer 
cells might also be partly due to the coagulation response induced by the host immune cells. It 
has been shown that during systemic infections immune cells embedded in the fibrin-rich 
microthrombi indeed trigger a coagulation response that aims to capture the bacteria for efficient 
elimination61,86. In line with this, microthrombi formed by the host immune cells could partly 
help in the entrapment of the tumour cells and thus facilitate their killing. On the other hand, 
fibrin production by the cancer cells could also be an immune escape mechanism by building a 
fibrin shield surrounding the cancer cells40,87. Our results show that the fibrin formation was 
triggered already after 2 h of injection of the cancer cells. However, at this time point the fibrin-
covered intravascular area was still limited and thus could potentially expose the cancer cells and 
their EVs to elimination by cytotoxic CD8+T cells or NK cells. At the same time point the 
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cancer cells were seen to be arrested in the microvessels, but did not cause any occlusion to 
impede the blood perfusion. Therefore, it is likely that the cancer cells at this time point are more 
accessible to the killing by NK cells and CD8+T cells. In accordance with the earlier results, the 
peak of arrival of NK cells and CD8+T cells was also observed 2 h after tumour cell injection. In 
addition, the apoptotic index was maximum at this same time point and this index was seen to 
decrease upon NK cell depletion. Overall, these results indicate that cancer cell elimination 
occurs already after 2 h of injection and that NK cells are eminently involved in the killing of 
cancer cells. Importantly, these results show that the elimination of the tumour cells occurs 
inside the blood vessels. 
The cancer cells which are arrested in the microcirculation are strongly associated with the 
microvascular fibrin formation also at the peak of intravascular coagulation activation, 6 h after 
the injection of the tumour cells. As one of the consequences of co-localisation of the cancer 
cells with the microthrombi, the microvessels are often occluded as comprehended from the 
‘stop’ in the blood perfusion. It is likely that this results in the formation of hypoxic areas in the 
vicinity of the blockage. Such hypoxic conditions are known to favour the survival and 
extravasation of cancer cells31,88. The role of immune cells that are rapidly recruited to the 
tumour cells arrested in the microcirculation needs to be further elucidated. Interestingly, we 
have seen that the extravasation of tumour MVs can already occur relatively early (2 h time 
point) although to a very limited extent. This suggests that MVs escape the immune surveillance 
and extravasate in the tissue probably to the areas of pre-metastatic niche formation. The exact 
mechanisms of the extravasation of MVs are not known. We observed that Kupffer cells 
engulfed most of the tumour cell-derived EVs. Besides this, other immune cells for example 
neutrophils and patrolling monocytes also engulfed tumour derived-EVs and transported them to 
the perivascular tissue. In general, the release of EVs from pancreatic cancer cells might 
contribute to their metastatic potential. This is indicated by the preliminary data on the release of 
oncosomes in the supernatants, of different pancreatic cancer cell lines. 
Moreover, the survival of the cancer cells and their EVs was also studied in long term 
experiments in which the livers were analysed, by immunohistochemical procedures, 14 days 
after the injection of the cancer cells and their MVs. It was seen that the cancer cells and the 
cancer MVs formed discrete foci in the perivascular space. These foci could be the starting point 
of the formation of pre-metastatic niches where the tissue could be remodelled to facilitate 
metastasis. In line with our previous results, we also saw that long-term experiments (3 weeks) 
with high doses of MVs showed the initiation of niche-like structures in transgenic mice models 
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of pancreatic cancer metastasis. Future experiments with longer incubation periods will be 
needed to give more information about the dynamics of the development of such foci as induced 
by injected cancer cell derived EVs.  
An important aspect of the present project was the identification of the immune cells that were 
rapidly recruited to the arrested cancer cells. We found that the first cells to arrive were CD8+T 
cells and NK cells (2 h after cancer cell injection). This suggested that the intravascular immune 
surveillance immediately aims at the killing of cancer cells. After the cytotoxic immune cells, 
inflammatory (classical) monocytes and a few hours later neutrophils were seen to be arriving. 
At the same time point the tumour MVs had already been engulfed by the Kupffer cells. The 
time line of the arrival of myeloid immune cells was confirmed in videos obtained from the 
intravital imaging. Beginning from 4 h after experimental tumour cell intravasation a strong 
increase in the arrival of GFP-labelled myeloid cells into the liver microvasculature was seen. 
The infiltrating myeloid cells showed varied behaviour upon encountering cancerous entities. 
Indeed, the myeloid cells interacted to a lesser extent with cancer cell clusters but extensively 
with small tumour cell fragments. These small tumour cell fragments were seen to be engulfed 
by the increasingly infiltrating GFP-labelled myeloid cells. This was especially evident in the 
CX3CR1-GFP-labelled mice where the labelled immune cells (mainly representing patrolling 
monocytes) appeared to patrol the walls of the microvessels and engulf the tumour EVs. This 
could either lead to the clearance of the tumour EVs or facilitate their extravasation, after being 
internalised by the immune cells, to distant potentially metastatic site40. Nevertheless, 
preliminary experiments indicate that at least a part of the cancer cells present in the 
microcirculation were propidium iodide (PI)-positive indicating that these had been killed. 
Therefore, NK cells might be majorly responsible for the killing of cancer cells in this model 
whereas the other myeloid cells might play a role in numerous other functions such as clearance 
of cancer EVs. 
Figure 37 summarises the principal findings of this thesis in relation to what is known about the 
haematogenic spreading of pancreatic cancer cells and their EVs. Pancreatic cancer cells 
disseminate from the site of primary tumour, escaping the immune-attack to intravasate into the 
blood circulation. In the microcirculation of organs such as the liver, which is the most preferred 
organ for pancreatic cancer metastasis, the cancer cells and their EVs are seen to be arrested. The 
arrested cancer cells locally activate fibrin formation by the blood coagulation system via PE-
dependent as well as TF-dependent or -independent mechanisms. Thereby, they can promote the 
occlusion of microvessels which may result in the formation of hypoxic areas. This in turn might 
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help to promote the extravasation of the cancer cells. In parallel, the arrested cancer cells release 
EVs, especially oncosome-like vesicles. Based on some previous and new findings the cancer 
cells and EVs which extravasate into the perivascular space contribute to develop metastatic foci. 
 
      
Figure 37: Schematic representation of the process of the intravascular events during pancreatic cancer metastasis 
depicting the role of EVs, microvascular fibrin formation and immune cells. The metastatic cancer cells and EVs 
(MVs and oncosomes) are seen to disseminate from the primary tumour and intravasate into the blood stream. Once 
they are arrested in the microcirculation of the organ where metastasis occurs the cancer cells start to locally 
promote fibrin formation. Consecutively, they are immediately attacked by NK cells and CD+8T cells. Other 
immune cells recruited to the arrested cancer cells are inflammatory monocytes, neutrophils and later patrolling 
monocytes. Most of the EVs are engulfed by intra- and extravascular macrophages. Arrested cancer cells extravasate 
and traverse towards the pre-metastatic niche area where the EVs have already remodelled the niche to promote 
cancer cell growth. The extravasated cancer cells settle in these areas, proliferate and begin the process of 
metastasis.  
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7. Summary 
 Metastasis is the most frequent cause of death in patients suffering from PDAC. In the present 
project, we focused on understanding the mechanisms promoting and counteracting metastasis of 
PDAC in the microcirculation of the liver, the main site of pancreatic cancer metastasis. In 
particular, the microvascular thrombus formation was studied with a focus on the procoagulant 
activity and localisation of cancer cells and their MVs. It was seen that KPC cells, a mouse 
pancreatic cancer cell line, and their EVs stimulate coagulation in a TF-independent manner. In 
contrast L3.6pl cells, a human pancreatic cancer cell line, and their EVs stimulated coagulation 
in a TF-dependent way. Yet both cell lines were shown to promote fibrin formation by 
presenting PE on their surface. This surface exposure of PE could be mediated by loss-of-
function mutations in P4-ATPases, which transfer PE to the inner leaflet of the plasma 
membrane since patients with PDAC show mutations in such P4-ATPases. 
 
To understand the consequence of stimulation of the coagulation cascade in vivo microvascular 
fibrin formation in the liver was analysed. Intravascular fibrin formation attained a peak 6 h after 
the administration of pre-labelled KPC cancer cells or their EVs. Fibrin formation was also 
analysed in vivo and in vitro by scanning electron microscopy. The results show that fibrin rich 
clots in the microcirculation of the liver indeed occlude the microvessels thus hindering the 
blood flow which may in turn deprive the surrounding tissue of nutrients. 
 
Cancer cells and their EVs were detected both in the intra- and extravascular areas of the liver 
microcirculation. A small proportion of KPC MVs are seen to extravasate early at 2 h. Yet most 
of the tumour MVs were rapidly engulfed by Kupffer cells. On the other hand, the KPC cancer 
cells were seen to be arrested in the liver microcirculation at 2 h and started to extravasate into 
the perivascular areas 6 h after administration. The extravasated EVs were immediately engulfed 
by tissue-localised myeloid immune cells. Other immune cells such as the NK cells, CD8+T 
cells, CD4+T cells and inflammatory monocytes were recruited to the intravascular cancer cell 
material 2 h after injection of cancer cells. At the same time point, apoptosis of cancer cells was 
maximal which appeared to be potentially related to the arrival of NK cells. Neutrophils, 
patrolling monocytes and other myeloid cells arrived in the circulation 6 h after injection of 
cancer cells and their EVs. Long term experiments with tumour cells and their EVs indicated that 
the tumour cells and their EVs clustered to form micro-metastatic foci in the perivascular tissue 
of the liver.  
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8. Zusammenfassung 
    Metastasen bilden die häufigste Todesursache bei Patienten mit PDAC. Daher lag der Fokus in 
der vorliegenden Arbeit darauf, die Mechanismen zu verstehen, die die Metastasierung des 
Pankreas-Karzinoms in der Mikrozirkulation der Leber regulieren. Insbesondere wurde das 
Entstehen von mikrovaskulären Thromben untersucht, wobei ein besonderer Schwerpunkt auf die 
prokoagulatorische Aktivität und Lokalisation von Krebszellen und deren MVs in den 
mikrovaskulären und perivaskulären Kompartimenten der Leber gelegt wurde. Es konnte gezeigt 
werden, dass KPC-Zellen (eine murine Pankreaskrebszelllinie) und ihre EVs, im Gegensatz zu 
humanen L3.6pl Zellen und ihren EVs, die Koagulation TF-unabhängig stimulieren. Hingegen 
wurde für beide Zellen nachgewiesen, dass die Stimulierung der Koagulation über die 
Präsentation des Phospholipids PE auf der Zelloberfläche gefördert wird. Dies könnte durch 
Mutationen in P4-ATPasen vermittelt werden, die PE in das innere Blatt der Zellmembran 
transferieren, da Patienten Mutationen in P4-ATPasen aufweisen. 
Um die Konsequenzen der in vivo Stimulation der Koagulationskaskade während der 
Metastasierung zu verstehen, wurde die mikrovaskuläre Fibrinbildung in der Leber analysiert. 
Nach Infusion von markierten KPC-Zellen bzw. ihren EVs erreichte die Fibrinbildung ihr 
Maximum nach 6h. Zusätzlich wurden durch SEM Experimente in vivo und in vitro die 
mikrovaskuläre Fibrinbildung visualisiert. Die Untersuchungen zeigen, dass fibrinreiche Gerinnsel 
in den Mikrogefäßen der Leber zur Okklusion der Gefäße führen können. Dadurch könnte die 
Versorgung mit Nährstoffen in den von den Mikrogefäßen versorgten Gewebsarealen 
beeinträchtigt werden. 
Weitergehende Analysen zur Lokalisation der KPC-Krebszellen und ihrer EVs in intra- bzw. 
extravaskulären Kompartimenten könnten dazu beitragen, die Vorgänge beim Entstehen einer 
prämetastatischen Nische besser zu verstehen. Ein kleiner Teil der MVs extravasierte bereits nach 
2h. Jedoch wurden zum selben Zeitpunkt 95% der MVs von Kupffer-Zellen aufgenommen. 
Krebszellen adhärierten an das Endothel der Mikrozirkulation ebenfalls bereits nach 2h. Später 
begannen die Karzninomzellen in die perivaskulären Areale zu emigrieren und dort Cluster zu 
bilden. Extravasierte EVs wurden sofort von myeloiden Immunzellen des extravaskulären 
Gewebes aufgenommen. In den mikrovaskulären Gefäßen beobachteten wir eine ebenfalls 
schnelle Rekrutierung von Immunzellen zu den adhärenten Karzinomzellen, so z.B. von NK-
Zellen, CD8+T-Zellen, CD4+T-Zellen und inflammatorischen Monozyten. Zu demselben 
Zeitpunkt war die Tumorzellapoptose maximal, was möglicherweise durch die rekrutierten NK-
Zellen induziert wurde. Neutrophile, patrouillierende Monozyten und andere myeloide Zellen 
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erschienen erst 6h nach Injektion der Krebszellen und ihrer EVs in der Mikrozirkulation. 
Langzeitexperimente mit den Krebszellen und ihren EVs zeigten, dass beide Tumor-Strukturen 
mikrometastatische Foci in der Leber bilden. 
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